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O-glycosylation is a post-translational modification misregulated in cancer 
and often correlated with poor prognosis and low overall survival. Particularly, 
truncated O-glycans, Tn and STn, are known as pancarcinoma markers. Their 
presence in surface proteins is well established in gastrointestinal (GI) cancer, 
which is currently one of the leading causes of death worldwide. The hyaluronic 
acid receptor, CD44, has critical roles in carcinogenesis, including GI cancer. This 
heavily O-glycosylated protein contains a vast repertoire of alternatively spliced 
variants whose detection/presence is tested in this thesis. In colorectal and 
gastric cancer (GC) tissue cohorts, CD44v9 has a cancer-specific detection, 
showing co-expression with STn. Using GC cell line models, the presence of 
CD44 variants is also characterized, through different immunodetection 
methods. CD44 variants detection is being influenced by the expression of 
truncated O-glycans. In a COSMC-/- genetic background, with homogenous 
expression of Tn and STn structures, there is an increased protein detection of 
CD44v9. These particular CD44v9 glycoforms are also more sensitive to trypsin 
and display higher cleavage rates. This finding has special relevance in cancer 
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development, providing promising directions to identify a serum biomarker. 
Furthermore, it enables future work regarding the influence of CD44v9 
glycoprofile on its malignant functions, adding higher level of specificity as a 
marker for GC diagnosis and therapeutic target. 
 











A O-glicosilação é uma modificação pós-traducional que está desregulada 
no cancro, sendo frequentemente correlacionada com mau prognóstico e com 
uma redução global na sobrevida. Em particular, Tn e STn, O-glicanos truncados, 
são notórios marcadores globais de cancro. A sua presença em proteínas de 
superfície está bem descrita no cancro gastrointestinal (GI), que é uma das 
principais causas de morte no mundo, atualmente. O recetor do ácido 
hialurónico, CD44, desempenha um papel crítico na carcinogénese, incluindo no 
cancro GI. Esta proteína extensamente glicosilada contém um repertório amplo 
de variantes, resultante de fenómenos de splicing alternativo, cuja 
deteção/presença demonstra ser influenciada pela expressão aberrante de O-
glicanos truncados, nesta tese. Em concreto, a presença de CD44v9 é específica 
de cancro em séries de tecidos de cancro gástrico e colorretal, mostrando 
coexpressão com STn. Adicionalmente, a presença de variantes de CD44 é 
caracterizada em modelos celulares de cancro gástrico. Num modelo genético de 
xiv 
 
COSMC -/-, que apresenta uma expressão homogénea de glicanos Tn e STn, 
observa-se uma maior deteção de CD44v9. No mesmo modelo é demonstrado 
que o CD44v9 é mais sensível ao corte proteolítico da tripsina e, numa análise ao 
secretoma, tem maiores taxas de clivagem. Esta observação tem especial 
relevância num contexto de desenvolvimento de cancro, fornecendo orientações 
promissoras para identificar um novo biomarcador serológico. Assim, esta tese é 
o ponto de partida para estudos futuros sobre a influência do glicoperfil do 
CD44v9 nas suas funções malignas, sendo que esta associação proteína/glicanos 
truncados pode melhorar a sua especificidade como biomarcador de diagnóstico 
de cancro gástrico e alvo terapêutico. 
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Cancer and Malignant Transformation 
Cancer is a disease that involves dynamic changes in the genome, that has 
been the subject of a global focus of attention regarding scientific and clinical 
research. Despite recent major advances in the unraveling of cancer and the 
development of novel treatments, many patients die due to the disease [1]. The 
leading cause of cancer death is a failure of drug treatments, as cancer cells 
become resistant to those drugs, which consequently limits the efficiency of 
chemotherapeutic agents [2]. Moreover, this therapeutic failure results in tumor 
recurrence and metastasis, that corresponds to the spread of cancer cells from the 
primary tumor to surrounding or distant organs, which is the cause of 
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To address the initial mechanisms underlying the emergence and 
development of malignant cells, Bishop and Weinberg identified in 1996 two 
classes of cancer genes that were altered in human and animal cancer cells. Those 
two classes of oncogenes were responsible for the production of cancer 
phenotypes in experimental models: some mutations produced oncogenes with 
dominant gain of function and some others originated tumor suppressor genes 
with recessive loss of function [5]. In humans, tumorigenesis is a multistep 
process that reflects somatic genetic alterations, driving the progressive 
transformation of normal cells into highly malignant byproducts [6]. 
There are more than 100 different types of cancer and within specific 
organs there are different cancer subtypes [7]. Cancer cells have defects in 
regulatory circuits, that usually control normal cell proliferation and 
homeostasis. In this way, the complex process that provokes malignant 
transformation is associated with a series of questions, including which and how 
regulatory circuits are affected. 
It is important to acknowledge tumors as complex tissues, since cancer 
cells not only have suffered critical mutational alterations, but also have recruited 
and subverted normal cells to serve as active collaborators in their neoplastic 
agenda. In fact, the essential changes in cell physiology that dictate malignant 
growth involve a set of diverse mechanisms. Six acquired alterations were first 
described to cause the vast catalog of cancer cell phenotypes that exist, including 
auto-generation of growth signals, resistance to growth suppressors, unlimited 
replicative capacity (immortality), evasion of programmed cell death (apoptosis), 
induction of angiogenesis, and capability of tissue invasion and metastization [8]. 
Later on, in 2011, conceptual progress added two emerging hallmarks that are 





reprogram cellular energetic metabolism and to evade immunological 
destruction [9]. Additionally, there are two consequential characteristics of 
neoplasia underlying both core and emerging hallmarks: genome instability, 
responsible for the genetic diversity that drives their acquisition, and 
inflammation, which nurtures multiple hallmark capabilities [9]. 
The interaction between the malignant cells and all the supportive 
partners and features of the tumor microenvironment is absolutely critic to 
understand cancer pathogenesis and to develop novel and more effective 
therapies. Therefore, acknowledge that there is extensive applicability of these 




As previously mentioned, cancer is the global notation of a vast and 
heterogeneous set of diseases characterized by the uncontrolled growth of 
abnormal cells within a tissue. It is still the greatest challenge of modern 
medicine, responsible for 9.6 million deaths only in 2018 [10]. 
Gastrointestinal (GI) cancer is one of the most significant causes of cancer 
death. In Portugal, colorectal cancer (CRC) and gastric cancer (GC) are the third 
and sixth more incident types, respectively. In terms of mortality, the scenario 
aggravates itself: CRC places in second and GC in fifth (Figure 1) [11]. The 
diagnosis of both gastric and colorectal cancers entails invasive procedures, such 


















Clinical Aspects of Gastric Cancer 
 Gastric cancer is one of the major threats to public health worldwide, with 
>780,000 deaths every year [12], and with over 1 million new cases in 2018 [13]. 
It has overall poor prognosis, with a 5-year survival rate of 20%, which reflects 
the lack of knowledge of its etiological factors and pathogenesis [14]. Moreover, 
early-stage stomach cancer rarely causes specific symptoms. This is one of the 
main reasons GC is so hard to be early detected. Most of the symptoms include 
nausea, poor appetite and weight loss, which are more likely to be caused by 
things other than cancer, such as a stomach virus or an ulcer [15]. Therefore, GC 
is associated with a consequent late diagnosis and lack of effective treatments 
[14]. In terms of risk factors, the main ones include infection with Helicobacter 
pylori (H. pylori), family history of stomach cancer or obesity [16]. 
 As said before, delays in diagnosis still seem to be common, virtually 
affecting the stage of GC at diagnosis as well as patient’s outcome. In most 
countries, where a screening program is not feasible, the diagnosis of GC and the 
Figure 1. Estimated age-standardized incidence and mortality rates (World) in 2018, Portugal, both 





selection criteria for endoscopy depends on alarm symptoms reported by the 
patient, that are not sufficiently sensitive to detect malignancies [17]. 
Gastric adenocarcinomas represent more than 95% of gastric 
malignancies. Since 1965, the histological classification of GC has been largely 
based on Lauren’s criteria, in which intestinal type and diffuse type 
adenocarcinoma are the two major histologic subtypes, plus indeterminate type 
as uncommon variant [18]. The relative frequencies are approximately 54% for 
intestinal type, 32% for diffuse type and 15% for the indeterminate type [19]. In 
the intestinal phenotype there is preservation of the glandular structure and cell 
polarity, whereas in the diffuse type these are lost [20]. The intestinal type is the 
most common form of GC and is associated with several risk factors, one of them 
being a cascade of neoplastic events triggered by H. pylori [16]. 
The diffuse type malignancies have no association with pre-neoplastic 
events and are thought to arise spontaneously. Tumors have poorly 
differentiated cells, with an infiltrative profile, resulting from low cell-cell 
adhesion related to E-cadherin loss of function [21, 22].  
In terms of metastasis, intestinal type GC preferentially metastasizes 
haematogenously to the liver, whereas the diffuse type migrates to the initial 
segment of the small intestine and establishes metastasis in peritoneal surfaces 
[18, 21]. 
In 2014, The Cancer Genome Atlas (TCGA) Research Network published 
an effort to further dissect the differences between GC subtypes, aiming to find 
the key players of the distinct types of GC, consequently improving the repertoire 
of available treatments [23]. By characterizing its molecular and genomic basis, 
they reached four classes of GC: 
CHAPTER 1. GENERAL INTRODUCTION 
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i. Epstein-Barr virus positive tumors, which show DNA hypermetilation 
and increased PD-L1 expression; 
ii. Microsatellite unstable tumors, resulting from germline mutations in 
DNA mismatch repair genes; 
iii. Chromosomally unstable tumors, with increased aneuploidy; 
iv. Genomically stable tumors, usually showing E-cadherin alterations. 
 Regarding treatment options, several pathways have been identified for 
each subtype described in the gastric cancer TGCA project, relatively different 
from each other and potentially targetable. Over the last decade, a number of 
novel agents of therapy have been examined in clinical trials, with largely 
disappointing results. This could be explained by the lack of molecularly selected 
trial populations or the weak predictive biomarkers that exist, within the context 
of a highly heterogeneous disease [24]. Despite that, the main treatment for GC 
patients continues to be surgery, either total or subtotal gastrectomy. Depending 
on the stage of the disease, chemotherapy or chemoradiation may be given before 
surgery, to try to shrink the tumor and make it easier to remove, and also as a 
treatment after surgery. In the metastatic setting, surgery should only be 
considered for palliation of symptoms [25]. Regardless of the heterogeneous 
features of this disease, all GC patients should be discussed at a multidisciplinary 
team meeting, concerning treatment options. Moreover, clinical trials and newer 
treatments may be an option and should always be considered. 
 
Clinical Aspects of Colorectal Cancer  
CRC is responsible for >860,000 deaths per year and, only in 2018, more 
than 1.8 million new cases have been diagnosed worldwide [26]. Unlike other 





majority of cases. In epidemiological studies, family history of CRC, 
inflammatory bowel disease, obesity, among others, have showed association 
with cancer incidence [27].  
Colorectal cancer, sometimes called colon cancer, combines both colon 
and rectal cancers, which begins in the rectum. CRC usually begins as 
noncancerous polyps formed on the inside of the colon, that may be small and 
produce few, if any symptoms. For this reason, it is recommended regular 
screening tests to help prevent CRC, by identifying and removing polyps before 
they progress to cancer. If CRC do develop, symptoms like rectal bleeding, 
persistent abdominal discomfort or unexplained weight loss may appear [28]. In 
terms of treatment, there are many options available that help to control the 
disease, including surgery and radio, chemo and immunotherapy [29, 30].  
CRCs are classified in terms of local invasion depth, lymph node 
involvement and presence of distant metastases. Also, they are discriminated 
accordingly between stages from I to IV. The presence of microsatellite instability 
or deficiencies in DNA mismatch repair genes can also be used to classify tumors. 
These genetic features result in higher immunoreactivity and immunotherapy 
has been tested for this cancer type [31].  
CRC is associated with a cascade of malignant events which transform the 
normal epithelia into a cancer tissue. The inactivation of the adenomatous 
polyposis gene (APC), usually through somatic mutation, is the first step of the 
sequence of carcinogenesis, resulting in the formation of early adenomas. The 
second event is the acquisition of a mutation in the Kirsten-ras gene (KRAS), 
which causes the formation of a mature adenoma. Finally, mutations in the Tp53 
gene lead to loss of p53-mediated pathways of apoptosis and there is progression 
to carcinoma (Figure 2) [32]. 












Figure 2. Schematic representation of colorectal carcinogenesis cascade. Adapted from [32]. 
 




1.2 KEY CANCER BIOMARKERS AND TREATMENT TARGETS 
 
Currently Used Markers and New Potential Markers 
 Nowadays, antibodies are being used in the medical treatment of diseases, 
such as cancer. They are a remarkable class of proteins that recognize molecular 
shapes with unmatched specificity and range. Many of the current biomarkers 
recognize glycan structures or glycoproteins, a feature that will be reviewed in 
section 1.3. Some examples of markers for gastric and colorectal cancer treatment 
and clinical tests include CEA (Carcinoembryonic antigen), CA-125 (MUC 16), 
CA19-9 (sialyl-Lewis a), CA 72-4 (STn), Tn-antigen and IGF-1R (Insulin-like 
Growth Factor I Receptor) [33 - 36]. 
If there is a high level of a tumor marker, it usually suggests that cancer 
may be present in the body. However, by itself, a high tumor marker level is not 
enough to make a diagnosis, being one of the reasons why international 
guidelines have not yet accepted tumor markers in the process of diagnosis of 
gastric and colorectal cancers [37].  
 Today’s technological age allows the usage of antibodies for virtually any 
target. Therefore, it is crucial to do an informed decision when choosing cancer 
specific therapeutic targets. One of the most promising approaches is to identify 
the cells with tumor-initiating capacities. Cancer cells within a tumor have a 
variety of fates that can range from death, proliferation, dormancy and/or 
exhaustion of clonal growth capacity [38]. However, the cellular origin of most 
solid tumors remains largely unknown. It has been speculated that distinct 
subtypes of cancer arise from different cells of origin at the time of tumor 
initiation.  
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 In a normal context, adult stem cells have an important role in physiological 
processes in many different somatic tissues [39]. There are three different 
proprieties shared by all stem cells: self-renewal (i.e., at cell division, one or both 
daughter cells retain the same biological properties as the parental cell); the 
capacity to differentiate into multiple lineages; and the potential to proliferate 
extensively [40]. In fact, tumor cells have high proliferative capacity, phenotypic 
plasticity and aberrant differentiation [38] and the similarities with stem cells 
have given rise to the hypothesis that tumors should arise from undifferentiated 
stem or progenitor cells. Therefore, malignant cells harboring stem cells’ features 
have been termed “cancer stem cells” (CSCs). 
 The CSC model proposes that tumors, like normal tissues, are organized 
in a cellular hierarchy. In this organized cellular system, CSCs are the only cells 
with unlimited proliferation potential and, therefore, capable of driving tumor 
growth and progression, cancer cell invasion and metastasis, and resistance to 
various forms of therapies, including radio, chemo and immunotherapy [40, 41]. 
 Therapy failure and relapse should not be solely attributed to the 
acquisition of novel mutations, but also to the surviving cells’ ability to 
regenerate the malignant tissue.  In fact, some studies demonstrated that CSCs 
become enriched following therapy, suggesting a selection process [38]. CSCs 
display higher resistance to cytotoxic chemotherapy, when compared to non-
CSCs, related to increased levels of drug transporters, enhanced DNA-damage 
repair mechanisms and the ability to escape the cytotoxic chemotherapy by 
maintaining a quiescent state. Combined with the capability of CSCs to evade the 
immune system [41] and to activate epithelial to mesenchymal transition (EMT) 
programs [20], it is clear that they are responsible for cancer aggressiveness, drug 
resistance and tumor relapse [38]. 




 Gastric and colorectal CSCs are the basis for the onset of each 
correspondent type of cancer. They may be derived from bone marrow 
mesenchymal stem cells, or gastric/colorectal stem cells, respectively.  
 Therapies that specifically target CSCs hold great promise for improving 
survival and quality of life for cancer patients. In various cancers, these cells are 
mainly identified using cell-surface markers expressed on corresponding normal 
stem cells. Many specific molecular markers have been used for identification 
and isolation of gastric and colorectal CSCs, such as CD44, CD133, Lgr5 and 
ALDH1 [42, 43]. These cells are highly tumorigenic, chemoresistant and 
radioresistant, being critical in the metastasis and recurrence of GC and CRC and 
disease-free survival [44]. However, not all the receptors named above gather 
consensus on their usage as cancer biomarkers. For instance, controversial results 
were reported where the CD133- cells where considered to be more aggressive 
[45, 46]. Also, Lgr5+ cells have been detected in both the population of normal 
intestinal stem cells and gastric cancer cells, in human, which is important to 
consider when the directed treatment is based exclusively on this biomarker [47]. 
Finally, observations were reported in which loss of ALDH expression was 
correlated with advanced stage of CRC [48].  
 Among the several known biomarkers, CD44 has unique features that 
make it one of the most promising tumor markers, with potential diagnostic and 
therapeutic applications. Therefore, those features will be carefully review in the 
next sections, being CD44 the focus of the work developed in this thesis. 
 Future therapies for gastric and colorectal cancers include the 
development of new targeted treatment therapies against membrane receptors, 
some of them already mentioned, to ultimately achieve the purpose of curing 
cancer patients. Moreover, molecular screening could help to fully characterize 
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cancers, identify the best prognostic panel of biomarkers and recognize patients 
suitable for specific targeted treatments. Nevertheless, the objective of future 
research is to detect biomarkers that can provide cost-effective and non-invasive 
cancer diagnosis. 
 
CD44 as a CSCs Marker 
 Interestingly, the first demonstration of CSCs in a solid tumor (breast 
cancer) showed that they were CD44+/CD24- [49] and the research for CSC-
specific markers gained momentum [38]. As already mentioned, markers for 
CSCs are associated with cancer-progeny, but CD44 has been shown to be 
present in CSCs of several types of malignant tissues, such as head and neck [50], 
gastric [51, 52] and colon cancer [53, 54]. CD44 (Cluster of Differentiation 44) was 
first identified as a lymphocyte homing receptor and is expressed in several cell 
types, being the major receptor that binds hyaluronic acid (HA) [55]. The binding 
of CD44 to HA influences many functions of the protein, often related to cell-
extracellular matrix crosstalk. It is a complex surface glycoprotein displaying 
high molecular weight heterogeneity, due to alternative splicing of a single CD44 
gene transcript and its differential glycosylation. 
 
CD44 Alternative Splicing 
 Alternative splicing occurs in the great majority of human genes and is an 
intricate process where exons are removed (spliced out) in the pre-mRNA 
molecule, being often misregulated during cancer progression [56].  
 The genetic annotation of the CD44 gene has been a controversial subject. It 
is consensually accepted that the full-length CD44 gene contains 19 exons, of 




which exons 1 to 5 and 15 to 19 are spliced together, encoding the two constant 
regions of the protein. Exons 6 to 14 can be alternatively spliced and assembled 
with the two constant regions to generate CD44 variants (CD44v), v2 to v10 
(Figure 3). When only the constant mRNA regions are transcribed, the 
ubiquitously expressed standard isoform of CD44 (CD44s) is generated. In some 
published work and revisions, it is claimed that CD44 has a 20th exon, exon 5a, 
relative to the v1 isoform. However, in human, exon 5a encodes a stop codon and 
is not expressed [56].  
 CD44s has a protein domain (first 3 exons) that binds to hyaluronic acid 
(HA), a stem region (exons 4, 5, 15, and 16), a transmembrane (exon 17) and a 
cytoplasmatic tail (exons 18 and 19) (Figure 4A). The variant exons encode 
protein domains in the proximal plasma membrane extracellular region but the 
regulation of the process that generates the different forms is not completely 
understood [57]. As CD44s is ubiquitously expressed, its usefulness as a CSC 
marker may be limited. Special attention has been given to CD44v isoforms as 




















Figure 3. CD44 Open Reading Frame and exon/protein domains correspondence. Adapted from 
[56].  
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CD44 Surface Cleavage 
 Shedding of cell-surface adhesion receptors is one of the modulator 
processes of cell–cell and cell–matrix adhesion, as well as in signaling pathways 
activation, which can transduce information of the crosstalk between the cell and 
its microenvironment. CD44 is a substrate of several proteases and can suffer 
sequential cleavages, resulting in the release of its extracellular domain 
(CD44ecd) and its intracellular domain (CD44icd). When the protein is intact, 
CD44ecd interacts with the extracellular matrix and the CD44icd associates with 
the actin cytoskeleton [55]. Upon extracellular cleavage, CD44icd can localize to 
the nucleus and regulate transcription of target genes that promote tumor 
development, including CD44 itself. This establishes a positive feedback loop 














Figure 4. Schematic illustration of a full-length CD44 protein. (A) CD44 domains, relative positions and 
sizes are represented. The position of the three disulfide bonds is shown in grey. Adapted from [56]. 
(B) CD44 extracellular cleavage, that results in ① release of extracellular domains and, after a 




region (224 a.a.) 
variable region (381 a.a.) 
stem (44 a.a.) 
transmembrane 
domain (23 a.a.) 
cytoplasmatic tail (70 a.a.) 




 CD44 shedding is observed in a variety of human tumors in vivo, including 
colon, and a strong positive correlation between the presence of CD44v and 
cleaved CD44 was observed [59]. As a consequence of cleavage, serum (cleaved) 
CD44 could be used as a biomarker of tumor burden, as it was suggested for 
gastric and colorectal cancer in the 90’s [60].  
 
Therapeutic applications based on CD44 
 As described in this thesis, CD44 has several features that make it a 
promising therapeutic target for cancer treatment. Its clinical applications are 
diverse and encompass different types of cancer. Antibodies targeting different 
epitopes of CD44 have been generated and used in pre-clinical studies. Roche has 
developed a novel functional monoclonal antibody (MAb) (RO5429083) which 
targets a glycosylated, conformation dependent epitope of CD44 in the constant 
region of the protein [61]. Based on pre-clinical studies it was approved and it is 
being currently used in clinical trials in several types of cancer, including GC and 
CRC [62].  
 The MAb U36 was shown to target the squamous cell-specific CD44v6 
[63]. This clone was labeled with indium-111 and intravenously injected to nude 
mice bearing head and neck squamous cell carcinoma (HNSCC) xenographs, 
expressing CD44v6, and the MAb U36 had significantly higher uptake in tumors 
[64]. However, not all CD44-based therapeutic applications showed successful 
results. An example is the CD44v6-specific MAb, Bivatuzumab, conjugated with 
mertansine, a drug designed to treat patients with incurable HNSCC. The main 
limiting toxicity of this CD44-targeted drug delivery compound in Phase I 
clinical studies was severe skin reactions (desquamation), including one fatal 
case of toxic epidermal necrolysis due to massive apoptosis of skin keratinocytes. 
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These complications resulted from an abundant ‘off-target’ expression of the 
CD44v6 antigen in normal squamous cells, with the main toxicity of 
bivatuzumab mertansine being directed against the skin, and caused an early 
termination of clinical development of the MAbs [65].  
 
Relevance of CD44 in Gastrointestinal Cancer 
 CD44 several forms (CD44s and the multiple CD44v) are one of the most 
promising targets for therapy, being of great functional importance in 
mechanisms of cancer development.  
 CD44 variants have been reported in gastrointestinal cancer and their 
expression was found to correlate with poor prognosis in patients. Back in 1993, 
Heider et al. described the expression of CD44v in sporadic gastric cancer tissues 
[66] and Mayer et al. demonstrated the positive correlation between CD44v9 
expression at time of diagnosis and distant metastization in primary gastric 
carcinomas [67]. In seminal work, Ishimoto et al. demonstrated that the presence 
of CD44v conferred resistance to ROS in a panel of GI cancer cell lines. The same 
group had published, one year before, work where they found that CD44v (v6–
10, v7–10, and v8–10) were preferentially expressed in gastric tumors of Gan mice 
(a genetic model for gastric tumorigenesis) [68]. Following those findings, they 
presented evidence that the CD44v isoforms interact with a glutamate-cystine 
transporter, xCT, to control the intracellular glutathione levels, which are related 
to protection against ROS. Indeed, forced expression of CD44v8–10, but not that 
of CD44s, promoted ROS resistance, enabling proliferation of gastric CSCs [69]. 
Lau et al. isolated CD44+ CSCs from patient tumor samples and observed that 
CD44v8-10 was the major CD44 variant found in those cells. Furthermore, they 
confirmed the previous findings relating CD44v8-10 with ROS resistance [70].  




 CD44v9 has been used in several cancer types, commonly as a CSC 
marker, with its presence often associated with poor prognosis and survival. In 
pancreatic cancer and adult T cell leukemia in vitro assays CD44v9 showed co-
expression with the multidrug resistance protein 1, which conferred resistance to 
therapy [71, 72]. In duodenal adenocarcinoma tissue samples, CD44v9 positive 
cells showed low mitotic activity and increased resistance to apoptosis [73]. In 
ovarian cancer, the presence of cleaved CD44v8-10 in ascites fluid was associated 
with metastization [74]. CD44v9 is highly expressed in GC and consistently it is 
observed that its presence is related with elevated tumor sizes, poor prognosis 
and survival [75, 76]. Moreover, it has been identified as a predictor of tumor 
recurrence in several GC cohorts [75] and silencing of CD44v9 expression is a 
novel pathway for treating GC [77]. Nevertheless, its role in colorectal cancer has 
also deserved focus. Like in GC cell models, CD44v9+ cells generate aggressive 
tumors in tumorigenic assays using CRC cell lines [54]. The expression of CD44v9 
was observed in circulating human CRC cells, that have CSC potential, and it 
was shown to be a potent marker in predicting recurrence, prognosis, and 
treatment efficacy [78]. The mechanistic importance of CD44v9 reveals a clear 
and promising target in biomarker discovery and therapeutic strategies in GI 
cancer. 






 Glycosylation is the enzymatic process responsible for the attachment of 
glycans (carbohydrates) to proteins, lipids or other saccharides [33]. This major 
post-translational modification, that can act as a key regulatory mechanism 
controlling both physiological and pathological processes, occurs in the 
Endoplasmic Reticulum (ER)/Golgi compartment of essentially all cells. It is 
mediated by the coordinated action of a portfolio of different glycosyltransferase 
and glycosidase enzymes that, in a series of steps, form carbohydrate structures. 
Most of these steps depend on substrate availability, enzyme activity, levels of 
gene transcription and enzyme location within organelles [79]. The glycome, that 
comprehends the entire complement of glycan structures in an organism, differs 
from the genome and the proteome. In fact, in terms of expression, the glycome 
is produced in a non-templated manner and is intricately controlled at multiple 
levels in the ER and Golgi apparatus. The complexity is further increased with 
metabolism-dependent transport of monosaccharides, feed-back loops that 
control glycogene-expression and even the physical conditions within the ER and 
Golgi lumen features [80]. Thus, Glycobiology is the science that studies the 
intricate processes that gives rise to structure, biosynthesis and biology of 
glycans and glycoconjugates. 
 Glycan vast diversity arises from differences in monosaccharide 
composition, in linkage between monosaccharides, in branching structures, 
among others. In fact, glycoconjugates are primarily defined according to the 





 Within the main glycoconjugates are included the glycoproteins, where 
one or more glycans are covalently attached to a polypeptide backbone 
predominantly via nitrogen (N) and oxygen (O) linkages, in which case they are 
known as N-glycans or O-glycans, respectively [81, 83]. Other major classes 





 The most common constituents of glycans are hexoses, that are composed 
of six carbon atoms [84]. Glucose (Glc) is a convenient reference compound when 
comparing these structures, as many of them can be derived from glucose by a 
single epimerization (a change in the stereochemical configuration of a single 
carbon atom in a sugar), substitution or addition/loss. For example, mannose 
(Man) derives from an epimerization at the 2 position, while epimerization at the 
position 4 yields galactose (Gal). On the other hand, a substitution of the 2-
hydroxyl group of glucose or galactose for an acetylated amino group gives rise 
Figure 5. Schematic representation of the common classes of glycoconjugates in mammalian cells. 
Adapted from [33]. 
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to N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc), 
respectively, while the loss of the 6-hydroxyl group and a change of 
configuration creates fucose (Fuc). Finally, it is important to mention the 
existence of sialic acids, a large family of sugars. N-acetylneuraminic acid 
(NeuAc), the most common form, is a nine-carbon sugar acid that is usually 
found in a six-member ring configuration. The several and unique substituents 
extended from the ring will give rise to other forms of sialic acid [81]. 
 The sugar components of glycoconjugates modulate a variety of functions 
in physiological and pathophysiological states, in addition to forming important 
structural features [80]. On the outmost surfaces of cellular and secreted 
macromolecules, where most glycans are found, they regulate receptor turnover, 
affinity and signaling [85]. These highly dynamic protein-bound glycans are also 
abundant in the nucleus and cytoplasm of cells, exerting regulatory effects [86]. 
Of the many molecular mechanisms that drive the formation of glycoconjugates, 
the next section will focus on the O-glycosylation, which is the most relevant for 
the scope of the work presented in this thesis. 
 
O-type Glycosylation  
 O-glycosylation consists in the addition of a sugar molecule to the oxygen 
atom of serine (Ser) or threonine (Thr) residues in a protein. There can be several 
types of O-glycosylation, depending on the monosaccharides that are first 
attached to the protein amino acids and the type of extension that occurs from 
there. In humans, the monosaccharides that most commonly initiate O-
glycosylation are GalNAc and GlcNAc [87]. The initial findings about this type 
of glycosylation were on mucins, heavily O-glycosylated proteins found in 





Figure 6. Schematic representation of the elongation process of O-GalNAcylation. Adapted 
from [90] 
have peptide repeats rich in O-GalNAc acceptors, which enables the conjugation 
of glycan structures, through O-GalNAcylation [80]. This type of O-glycosylation 
is one of the most diverse forms of posttranslational modification involving up 
to 50-100 distinct genes. The first step alone is performed by up to 20 polypeptide 
GalNAC-transferases [83] and, from there, the extension process can give rise to 
several different structures (Figure 6). The single GalNAc attached to a Ser or Thr 
is called the Tn antigen. When the Tn antigen is elongated with a ß1,3-Gal, by the 
C1GalT1 transferase, the T antigen structure is formed, which can be further 
elongated, resulting in a core 1 O-glycan. C1Gal-T1 3galactosyltransferase is 
unique in requiring a private chaperone COSMC for folding and catalytic 
function. Core 2 O-glycans contain a branching GlcNAc in the T structure, that 
can also be extended. Core 3 and 4 structures have one or two GlcNAc-initiated 
branches, respectively, starting from the Tn antigen [87]. Although cores 1 to 4 
correspond to the four most common O-GalNAc glycan core structures found in 
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 The elongation of the many initial core structures is carried out through 
the action of different glycosyltransferases that extend the existing structure with 
Gal, GlcNAc, sialic acid or even fucose, as the protein moves through the cis-, 
medial- and trans-Golgi compartments [87]. These GalNAc-linked glycan 
structures are abundant on many secreted and extracellular proteins and have 
been shown to participate in several key biological processes of organ 
development and function [88]. The extensive glycosylation protects both the 
glycoproteins and cellular surfaces from external stress, as it forms an important 
interface between epithelial cells and the external mucosal surfaces of the body. 
For instance, in secreted mucins on epithelial cells, O-glycans are responsible for 
hydration of the layer [91]. It is well established the role of mucin O-glycans in 
selectin-mediated cell adhesion in immunity [92]. Also, knockout mice for the 
C1GalT1 transferase died by embryonic day 14, due to impaired vasculature 
formation [93].  
 O-GlcNAc-linked glycans are typically found on intracellular 
compartments, including the cell nucleus, mitochondria and cytoplasm. Unlike 
the mucin-type O-glycans, the addition of GlcNAc does not occur in the Golgi 
apparatus and is typically not extended. Instead, it is regulated through the 
action of the O-linked GlcNActransferase (OGT) and the O-linked GlcNAcase 
(OGA), that perform a rapid cycle of addition and removal of GlcNAc from 
protein substrates [94]. This process is known to compete with protein 
phosphorylation at Ser and Thr residues, impacting several cellular regulatory 
functions, including cellular metabolism [95]. 
 Briefly, another type of O-glycosylation consists in monosaccharides 





family of protein O-mannosyltransferases (PMTs) and takes place in the 
endoplasmic reticulum (ER) [96]. 
 
Glycosylation in disease 
 At this point, it is clear that glycosylation is critical for both physiological 
and pathological cellular functions [97]. Indeed, there are many examples of 
diseases associated with aberrant glycosylation or failure of carbohydrate 
recognition systems [98]. Being genetic in origin or acquired through somatic 
mutations, they can affect virtually all cells in the human body, having a systemic 
impact [99]. 
 Congenital disorders of glycosylation (CDGs) are inherited conditions 
that are quite rare, being often embryonic lethal [100, 101]. However, they have 
been recognized due to changes in glycosylation of serum glycoproteins, such as 
the iron-binding blood plasma transferrin, that controls the level of free iron in 
biological fluids [102]. CDGs can be categorized into two different types, both 
derived from mutations in enzymes for N-glycans synthesis [103]. In the first one, 
normal N-glycans are attached to serum glycoproteins but in a small percentage 
of all the potential N-glycosylation sites. The second group consists of syndromes 
in which all or most of the usual glycosylation sites are utilized, but the attached 
glycans are reduced in size and complexity [104, 105]. Although these syndromes 
provide limited insights into the exact functions of glycans, they confirm that 
complex glycans have crucial roles in development [106].  
 Another disorder that is genetic in origin is the von Willebrand factor 
deficiency. It is a relatively common bleeding disorder that results from a two- to 
five-fold reduction of this factor in serum levels. The von Willebrand factor is 
essential for initiate the blood-clotting cascade but, in case of disease, the small 
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amount of the factor that is present, although having a normal activity, leads to 
excessive bleeding following wounding. Glycosylation plays a critical role 
regarding this deficiency. Galgt2 N-acetylgalactosaminyltransferase, an enzyme 
normally found in epithelial cells, can suffer a mislocalization to endothelial cells, 
due to a change in the coding region of the GalNAc transferase gene. This 
alteration occurs at a single genetic locus and the dominant mutant gene is 
inherited in simple Mendelian fashion [107]. Therefore, von Willebrand factor, 
that is made in endothelial cells, where it normally does not encounter that 
glycosyltransferase, will receive terminal GalNAc residues. This   abnormally 
glycosylated factor will be then cleared from circulation. The mislocalization of 
GalNAc transferases is probable to cause aberrant glycosylation of not only the 
von Willebrand factor but several different proteins in the endothelial cells [108].  
Further examples involve chemical reactions of sugars, immunological 
responses to them and diseases in which glycosylation changes are correlated 
with disease phenotype, but where a causal connection is not yet clear. In the 
normal forms of glycosylation, the addition of glycans to glycoproteins requires 
the action of specific glycosyltransferases. However, a direct chemical reaction of 
monosaccharides with proteins can occur. These so-called glycation reactions are 
generally inefficient, and their products have a very distinct nature when 
compared to the chemical features of N- and O-glycans [109]. Therefore, they are 
only observed under special circumstances, such as when glucose levels become 
very high in diabetic patients or in proteins that have long half-lives. 
 The impact of glycans extends into immunity and inflammation. As one 
would expect, there are glycoconjugates found on the surface of innate and 
adaptive immune cells, that can sense environmental signals. On the other hand, 





expressed on the surface of microorganisms, including bacterial 
lipopolysaccharides, peptidoglycans, fungal mannans and teichoic acids [110]. 
Glycans are known to have different roles that are essential for the differentiation 
of B and T cells. In fact, the immunoglobulins that are secreted by B cells, and 
vital components of humoral immunity, are glycoproteins with specific 
glycosylation patterns [111, 112]. Defects on these patterns or alterations in 
glycan composition can contribute to immune dysregulation, leading to a range 
of autoimmune, infectious or chronic inflammatory diseases, such as systemic 
lupus erythematosus [113], HIV infections [114] or rheumatoid arthritis [115]. 
 Another rare blood disorder of O-glycosylation, that is acquired and 
permanent, is the so-called Tn syndrome [116]. It is characterized by the presence 
of Tn immature antigens on glycoconjugates of all hematopoietic cell lineages 
and can affect both males and females at any age. In this disorder, the Tn antigen 
is over-represented due to a clonal somatic mutation in COSMC, which encodes 
a molecular chaperone essential for C1GalT1 function. This reduces the amount 
of active C1GalT1, leading to a decrease in the galactosylation of terminal 
GalNAc, thus accumulating Tn antigens [117, 118]. These truncated glycan 
structures are recognized by IgM antibodies, causing different degrees of anemia, 
leukopenia and thrombocytopenia in affected patients [116].  
 Finally, one of the subjects that deserves special attention in terms of 
glycobiology is Cancer. There are several well-known alterations in 
glycoconjugates associated with the malignant process, that will be discussed in 
detail further in the next section. 
Alterations in the glycosylation can have remarkably subtle and indirect 
effects. Although these changes might be global, phenotype associated with such 
alterations are often most evident for one or a few proteins. To uncover the 
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defects and disorders involving glycosylation will bring us closer to understand 
its basic mechanisms, allowing the association between specific glycoconjugates 
and disease phenotypes [86]. Besides, knowing the importance of glycans in 
human cellular processes opens new possibilities in terms of diagnosis and 
treatment of several diseases. 




1.4 GLYCOSYLATION IN CANCER 
 
Tumor-associated Alterations  
 Cancer cells often present a range of glycosylation alterations that lead to 
oncofetal phenotypes, as they resemble glycoprofiles in early development [33]. 
Malignant transformation is associated with aberrant glycosylation virtually in 
all tissues, being the neo-synthesis and the formation of immature truncated O-
glycan structures the most common phenotypes [33, 86].  
 Neo-synthesis results from the induction of transcription of specific genes 
involved in the expression of carbohydrate determinants. This leads to de novo 
expression of abnormal glycoprofiles, containing sialyl Lewis X structures for 
instance, which can promote the metastatic process [33, 84].  
 Complex and elongated O-glycans contribute to protein stability and 
function, so the absence of these structures has obvious functional implications. 
In fact, truncated O-glycans have been under the spotlight regarding cancer 
research. Therefore, their biological role in malignant tissues will be dissected 
below.  
 Other glycoprofile alterations associated with cancer cells are abnormal 
core fucosylation and increased N-glycan branching [33]. 
 
Mechanisms for O-Glycan Truncation 
 The surface expression of early intermediates of the O-glycosylation 
pathway, the so-called immature or truncated O-glycans, is one of the most 
common phenotypes of malignant cells. The expression of truncated O-glycans 
is strongly correlated with poor prognosis and low survival and are present in 
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most gastric [33, 119, 120] and colorectal cancers [121, 122]. In fact, the Tn, STn 
and T glycan structures have been considered pancarcinoma antigens [123]. Tn 
and STn promote cancer progression or protection from the surveillance of the 
immune system, hence being valuable therapeutic targets in clinical treatment 
[33].  
 A number of different mechanisms may underlie this characteristic change 
in glycosylation, including altered expression of glycosyltransferases involved in 
branching and capping [124, 125], general reorganization of glycosyltransferase 
topology [126, 127], as well as fluctuations in cellular pH [128, 129].    
 One of the most explored mechanisms is the reduction of core 1 elongation, 
due to a blockade in the production of the T structure. Work on Tn positive cancer 
cell lines and patients with Tn syndrome revealed loss-of-function mutations in 
the COSMC gene and loss of T-synthase [121]. Promoter hypermethylation of 
COSMC was also identified in Tn-positive human pancreatic cancers [130]. Also, 
defective COSMC function results in aggregation and proteasomal degradation 
of the T-synthase, blocking glycan formation in the Tn antigen stage [118]. 
 If not further modified by the T-synthase, the Tn antigen faces only the 
action of the ST6GalNAc glycosyltransferases. The expression of the sialylated 
form of Tn, STn, which serves as a biosynthetic stop, is likely controlled by the 
sialyltransferase ST6GalNAc-I [127]. Although this enzyme is also expressed in 
normal cells, overexpression appears to be needed to override the elongation 
pathway [125].  In fact, overexpression of ST6GalNAc-I is seen in intestinal 
metaplasia of GC and colon carcinomas, which colocalizes with STn positive cells 
[131]. 
 Another mechanism for O-glycan truncation is the mislocalization and/or 
expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases 




(ppGalNAcTs), the enzymes responsible for the UDP-GalNAc addition to a Ser 
or Thr in the peptide backbone. For instance, in murine colon carcinoma cells, 
loss of ppGalNAcT 3 resulted in O-glycan truncation and promoted metastasis 
to the liver [132]. 
 Glycoproteins expressing the abnormal O-glycan Tn antigen may have 
altered structure and stability and be stably expressed on the membrane. 
Therefore, the expression of Tn and STn antigens in glycoproteins, instead of 
normal elongated O-glycans, can lead to altered expression and function of the 
protein carrier.  
 
Models to Study Glycosylation in Cancer 
 Glycans play critical functional roles in host–pathogen interaction, 
progression of malignancies and embryonic development. Models to study the 
glycosylation contribution in biological processes are necessary for research. 
  Mouse knockout models and transgenics have been used to study the 
impact of specific carbohydrate deficiencies in several processes [133]. Cell lines 
derived from tumors have also been employed for the research of glycosylation’s 
role. Jurkat cells, derived from human leukemia, have a mutation in the COSMC 
gene and were used for the initial studies of O-glycosylation truncation [134]. 
Interestingly, it was observed that in CRC bulk cell cultures Tn positive cells were 
present as a subpopulation, harbouring mutations in COSMC [121].  
 The use of programmable nucleases revolutionized all fields of scientific 
research, and the study of glycans was no exception. Zinc finger nucleases 
(ZFNs) were used to generate knockout cell lines for COSMC [135], the so-called 
SimpleCell (SC) model, including in MKN45 gastric cancer cells (Figure 7A, B) 
[119]. Recently, a library of gRNAs targeting human genes of the glycosylation 






machinery using CRISPR/Cas9 was published [136].  
 Other genetic tools, such as RNA-interference and plasmid-induced gene 
expression, were also shown to be able to generate cell lines to investigate 
glycosylation modifications [131, 137]. Examples of these include the knockdown 
of COSMC, which enriches O-glycan structures to the Tn and STn antigens [131]. 
Also, ST6GalNAc-I overexpressing plasmids were stably transfected in MKN45 
GC cells, so the Tn glycan is preferentially used as a target by the ST6GalNAc-I 
transferase, favoring the formation of STn and competing with the O-glycan 














 These models are essential to study global phenotypes of cancer, including 
the glycosylation role in specific proteins, as it will be discussed in the next 
section. 
Figure 7. Schematic representation of the mucin-type O-glycan biosynthesis pathway (A) in the MKN45 
gastric carcinoma cell line control models, MKN45 wild type (WT) and MKN45 MOCK transfected 
cells. The mechanisms by which O-glycans have been truncated in the applied MKN45 cell line models 
gave rise to (B) the MKN45 SimpleCell model and (C) the MKN45 ST6GalNAC-I model. MKN45 cells 
naturally have the absence of core 3 and 4 O-glycans expression.  




CD44 Glycoforms in Cancer 
 As previously mentioned, CD44 is a global marker for CSCs and a potential 
cancer biomarker for diagnosis and treatment. Its structural heterogeneity 
derives from alternative splicing events but is further amplified by extensive and 
often isoform-specific glycosylation. CD44 variable isoforms may carry N-
glycans (9 predicted and validated sites), O-glycans (146 predicted and 56 
validated sites) and glycosaminoglycans (2 predicted and validated sites) (Figure 





 There is missing knowledge on the influence of the glycoprofile of CD44 on 
its function. Gasbarri et al. modulated the N- and O-glycosylation pathways and 
observed, in melanoma cell lines, that spontaneous CD44 shedding was 
dependent on the presence of its O-glycosites on the membrane-proximal 
domain [138]. Mereiter et al. showed that the affinity of CD44 to HA was higher 
when cells expressed immature O-glycan structures, which promoted cell 
motility and invasion [139]. 
 Using the SC model, a glycoproteomics strategy to explore potential 
biomarker O-glycoproteins was published, including the secretome of two GC 
cell lines, AGS and MKN45. CD44 was identified in the gastric cancer SCs as a 
potential secreted biomarker O-glycoprotein with immature O-glycans. This was 
validated in cancer patients’ sera and the staining patterns of CD44 and STn 
Figure 8. Validated O-glycan sites annotation of the full-length CD44 Open Reading Frame of CD44. 
The information is according to the GlycoDomain viewer database.  
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overlapped in gastric tumor sections. Interestingly, the single O-glycosite 
identified by mass spectrometry in CD44 was in the v9 exon [119]. 
 Glycosylation has gained more and more attention in several research 
fields, including cancer development and progression, of which, with 



















 Colorectal and gastric carcinomas are the third and fifth most common 
cause of cancer death worldwide and remain among the leading cancers in 
incidence and mortality. This reflects the late diagnosis of these types of cancer, 
due to appearance of clinical symptoms only when the cancer has progressed. To 
overcome this problem and improve patient care and overall prognosis, 
discovery of new and better characterized biomarkers is pivotal.  
 The lack of success in validating many of the new promising targets such 
as CD44v, often arise from impaired methods of its detection/targeting. 
Structural and functional heterogeneity, generated by alternative splicing and 
glycosylation, makes CD44 one of the most variable surface molecules. This 
provides the explanation for its various cellular functions, but it also may explain 
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show how this structural heterogeneity cannot be neglected on detection 
methods of this target.  
 
General Aim 
To characterize CD44 variants expression in gastric and colorectal cancers and to 
evaluate the potential of CD44v9 cancer-associated glycoforms detection 
methods for future clinical application in gastrointestinal cancer.  
 
Specific Aims 
1. Characterize CD44 variants and truncated O-glycan antigens in gastric and 
colorectal cancer tissues 
From a biomarker perspective, it is necessary to investigate selected targets in 
tissue samples as well as their cancer specific glycoforms. Therefore, in chapter 4 
section 4.1 it is performed an immunohistochemical characterization of CD44v9 
in colorectal tumor tissue microarrays (TMAs) and gastric carcinoma tissues. Co-
expression and co-localization of CD44v9 and the truncated O-glycan antigens 
Tn and STn is evaluated in a gastric cancer series.   
 
2. Evaluate CD44 isoforms expression in gastric and colorectal cancer cell line 
models to assess whether it correlates with a glycoprofile 
During the process of novel biomarkers discovery, in vitro characterization is 
crucial to validate immunohistochemical analysis of patients’ samples. Thus, in 
chapter 4 section 4.2 the influence of O-glycosylation in molecular features of 
CD44 and its variant isoforms is assessed, using the SimpleCell and the 
ST6GalNAc-I overexpressing models, representing different strategies of O-
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glycosylation elongation disruption. Furthermore, it is evaluated whether 
truncated O-glycans influence the transcriptional levels of CD44 genes.  
 
3. Detect CD44 extracellular cleavage and its relationship with O-glycan 
truncation and establish its biological biomarker potential. 
O-glycoproteins constitute many in use serum biomarkers and the detection of 
specific changed O-glycans, mainly truncated ones, may provide increased 
specificity of these structures. CD44 is cleaved in vivo and CD44v9 was detected 
in patient’s sera. In chapter 4 section 4.3 it is evaluated CD44s and CD44v9 
isoforms extracellular cleavage according to the complexity degree of O-glycans 
they express, in different gastric cancer cell lines. Moreover, the secretome 
analysis of those cell lines is performed, targeting the CD44/CD44 isoforms that 















MATHERIALS AND  METHODS 
 
3.1 CELL LINES 
 The gastric carcinoma cell lines MKN45 and AGS were obtained from the 
Japanese Collection of Research Bioresources and ATCC, respectively. The 
MKN45 and AGS SimpleCells (MKN45 SC and AGS SC) were obtained by 
targeting the C1GALT1 (COSMC) gene using zinc-finger nuclease precise gene 
editing as previously described [119, 135]. Besides, MKN45 cell line was stably 
transfected with the full length human ST6GALNAC1 gene (MKN45 ST6GalNAc 
I) or the corresponding empty vector pcDNA3.1 (MKN45 Mock) as previously 
described [140, 127]. The colorectal carcinoma cell lines RKO and LS-174T were 
obtained from ATCC. 
 All cells were grown in monolayer in uncoated cell culture flasks. Cells 
were maintained at 37 °C in an atmosphere of 5% CO2, in different media: AGS 















(Alfagene); MKN45 Mock (ST6) and MKN45 ST6GalNAC I also in RPMI 1640 
GlutaMAX™, HEPES medium, supplemented with 0.5 mg/ml of G418 
(Invitrogen, Waltham, MA) to select transduced cells; LS-174T in Dulbecco’s 
Modified Eagle Medium (DMEM, high glycose/pyruvate; Alfagene). All media 
were supplemented with 10% heat-inactivated FBS (Fetal Bovine Serum; 
Labclinics). Cell culture medium was replaced every two to three days. Cultured 
cell lines were routinely tested for mycoplasma contamination by PCR 
amplification for mycoplasma pulmonis UAB CTIP, mycoplasma penetrans HF-
2, and mycoplasma synoviae 53. 
 
3.2 PRIMARY ANTIBODIES 
 In western blot, dot blot, immunofluorescence, flow cytometry and 
immunohistochemistry (IHC) experiments the following primary MAbs have 




Antibody Clone Isotype Host Specificity/   Sensitivity Immunogen Source Ref. 
CD44 156-3C11 IgG2a Mouse 
Detects endogenous 















CD44v9 RV3 IgG2a Rat 
Detects human CD44 













Table 1. List of antibodies. 
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Tubulin DM1A IgG1 Mouse 
Detects the ~60kDa 
tubulin protein found in 
all eukaryotic cells 
Purified human 
brain α-Tubulin 
Merck [144]  
N.A. = not available; U.D. = Unpublished Data (Clausen and Hakomori) 
 
3.3 IMMUNOFLUORESCENCE 
 Immunofluorescence (IF) is a common microscopy-based technique that 
uses specific antibodies to label fluorescent dyes to specific biomolecules targets 
within a cell.  
 Cells were grown in coverslips, in 12 well plates, and fixed in 4% 
paraformaldehyde for 10 minutes as previously described and frozen at -20 °C 
until immunofluorescence performance [145]. Coverslips were permeabilized 
with PBS 0.2 % Triton X-100 for 10 minutes at RT, washed three times with PBS 
1x and blocked with goat serum (DAKO, Denmark) diluted 1:5 in PBS 10% BSA 
for 30 minutes at RT. Cells were incubated overnight at 4 °C with the 
corresponding primary MAbs: Tn and STn (undiluted); CD44s PanS (10 μg/ml) 
and CD44v9 (3 μg/ml), both diluted in PBS 5% BSA. After being washed 3 times, 
coverslips were incubated 1h at RT and in the dark with secondary antibodies: 
FITC-conjugated rabbit anti-mouse immunoglobulin (DAKO) diluted 1:100 in 
PBS 5% BSA for Tn, STn and CD44s PanS; donkey anti-rat Alexa Fluor® 488 
immunoglobulin (Invitrogen, Eugene, OR) diluted 1:500 in PBS 5% BSA, for 
CD44v9. Cells were washed 3 times with PBS 1x, incubated with DAPI (4′,6-
diamidino-2-phenylindole) diluted 1:100 in PBS for 10 minutes at RT, washed 2 
times and the coverslips were mounted with Vectashield mounting 
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medium for fluorescence (Vector, Burlingame, CA). Negative controls were 
performed by substitution of the primary antibody with PBS 5% BSA. Cells were 
visualized and images were acquired using Zeiss Optical Microscope 
 
3.4 WESTERN BLOTTING  
 The western blot (WB), or protein immunoblot, is an analytical technique 
that detects specific proteins in a biological sample or extract. 
 Cells were washed twice with PBS and directly collected in lysis buffer 17 
(R&D Systems, McKinley Place, MN) additionally supplemented with 1 mM 
sodium orthovanadate, 1 mM phenylmethanesulfonylfluoride and protease 
inhibitor cocktail (Roche, Basel, Switzerland). Protein concentrations of lysates 
were determined by DC protein assay (Bio-Rad, Hercules, CA), based on the 
Bradford dye-binding method [146] and a total amount of 25 μg of protein extract 
were used in each experiment. Samples were mixed with 6.25 μL Loading Buffer 
(Bio-Rad), 2.25 μL of DTT and denaturated in dry bath for 10 minutes at 90 °C, 
before being resolved in a 4-15% polyacrylamide precast gel (Mini-
PROTEAN®TGX™) at 100V for 1 hour, in 10x TrisGlycine/SDS buffer (Bio-Rad). 
Proteins were transferred to polyvinylidene difluoride (PVDF) membranes (GE 
Healthcare, Chicago, IL) at 330 mA for 1 hour, in 10x Tris/Glycine buffer (Bio-
Rad), using a Mini-PROTEAN® Tetra Cell System (Bio-Rad, Hercules, CA). The 
membranes were blocked with TBS with 0.1% TWEEN (TBS-T) containing 5% 
skim milk, followed by an overnight incubation with primary antibodies (CD44, 
CD44sPanS or CD44v9, at 1:1000, 1:2500 or 1:1000, respectively) in TBS-T. 
Membrane were incubated with peroxidase AffiniPure goat anti-mouse IgG 
(H+L; Jackson ImmunoResearch) in case of CD44 total and CD44s PanS primary 
antibodies, and with goat anti-rat IgG-HRP (Santa Cruz Biotechnology, CA, 
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USA) in case of CD44v9, at 1:5000 or 1:2000, respectively, in TBS-T. The signal 
was detected with ECL™ Western Blotting detection reagents (Amersham™, GE 
Healthcare) and high performance chemiluminescence films (Amersham 
Hyperfilm™ ECL, GE Healthcare), exposed in a Hypercassette™ (Amersham, 
Biosciences) and revealed and fixed with developer and fixer solutions, 
respectively. Densitometry was performed with GS-800 Calibrated Densitometer 
(Bio-Rad), values were normalized to tubulin and represented as relative values 
compared to the control, using the Image Lab software (Biorad). Results shown 
in Figure 14 are from a n = 2 independent experiments (for CD44 total antibody) 
or from a n = 4 independent experiments (for CD44s PanS and CD44v9 
antibodies).  
 
3.5 DOT BLOTTING 
 A dot blot represents a simplification of the western blot technique in 
which the proteins to be detected are not first separated by electrophoresis. 
 Protein lysates (from MKN45 WT/SC, MKN45 Mock/ST6GalNAc I and 
AGS WT/SC) were diluted in water for a total volume of 11 μl. PVDF membranes 
were prepared drawing grids by pencil to indicate the region that is going to be 
blotted. Samples were spotted onto the membrane at the center of each grid. To 
minimize the area that the solution penetrates, the procedure was made slowly, 
in two times (5.5 μl for each). The membrane was left to dry for 30 minutes. The 
blocking, incubation in primary and secondary antibodies, and signal detection 
procedures were performed as previously explained (see Western blot, materials 
and methods). Results shown in Figure 16 are from one experiment. 
 




3.6 PROTEIN ENZYMATIC DEGLYCOSYLATION 
 Enzymatic deglycosylation consist in the removal of carbohydrates from 
glycoproteins to simplify the analysis of the peptide portion of the glycoprotein, 
for instance.  
 Three different deglycosylation processes were performed, to remove 
different glycans from 25 μg of total cell protein lysates (RKO, MKN45 WT and 
MKN45 SC). 
 N-linked glycans were removed by denaturing the protein lysates with 
10x glycoprotein denaturing buffer (New England Biolabs) at 100 °C for 10 
minutes, chilling one ice, and by applying a deglycosylation mix composed of 10 
% G7 Glyco buffer (New England Biolabs), 10% NP-40 and 5% PNGase F (New 
England Biolabs), for a total volume of 30 μl. N-linked and O-linked glycans were 
removed by denaturing the protein lysates with 10x glycoprotein denaturing 
buffer at 100 °C for 10 minutes, chilling one ice, and by applying a 
deglycosylation mix composed of 10 % Glyco buffer 2 (New England Biolabs), 
10% NP-40 and 5% Protein Deglycosylation Mix II (New England Biolabs), for a 
total volume of 30 μl. The enzymes included in the deglycosylation enzyme 
cocktail are O-glycosidase, PNGaseF, α2-3,6,8,9 Neuraminidase A, β1-4 
Galactosidase S and β-M-Acetylhexosaminidase. Sialic acids were removed by 
directly applying Neuraminidase (0.2 U/ml) (Sigma-Aldrich, St. Louis, MO) 
diluted in PBS 10x, for a total volume of 26,5 μl. 
 All samples were incubated overnight at 37 °C in a total volume of 30 μl 
and analyzed in a Western blot for CD44v9 characterization. Densitometry was 
performed with GS-800 Calibrated Densitometer (Bio-Rad), values were 
normalized to tubulin and represented as relative values compared to the control 
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(MKN45 WT without deglycosylation treatment), using the Image Lab software 
(Biorad). Results shown in Figure 15 are from one experiment. 
 
3.7 SECRETOME ANALYSIS 
 The term secretome denotes all the proteins secreted by a cell to the 
extracellular space [147].  
 For the secretome analysis, cells were grown in medium without FBS 
supplementation. Conditioned media were collected after 48h and were enriched 
in protein content using 10 kDa Amicon Purification System (Merck Millipore, 
Burlington, MA). Afterwards, samples were quantified and analyzed in a 
Western Blot for CD44 total, CD44s PanS and CD44v9 characterization. 
Densitometry was performed with GS-800 Calibrated Densitometer (Bio-Rad), 
values were normalized to the staining of the bands with Ponceau S (Sigma-
Aldrich) upon protein transfer to the PVDF membrane and represented as 
relative values compared to the control (MKN45 WT), using the Image Lab 
software (Biorad). Results shown in Figure 21 are from one experiment. 
 
3.8 FLOW CYTOMETRY 
 Fluorescent-activated cell sorting (FACS) is a fluorescent-based method 
that allows the quantification of specific markers in a population of cells.  
 Cells were detached using Gibco® Versene solution (ThermoFisher, 
Waltham, MA) or trypsin solution (trypsin 0.05% EDTA, Alfagene) washed with 
FACS buffer (PBS 1x with 1% FBS) and centrifuged at 300g for 5 minutes at 4 °C, 
followed by the staining of dead cells with Fixable Viability Dye APC-Cy7 (FVD 
1:2000, ThermoFisher, Waltham, MA) for 30 minutes on ice. Afterwards, cells 
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were submitted to one of the following protocols: fixation only or fixation and 
permeabilization protocols. In the first protocol, cells were stained with primary 
antibodies diluted in FACS buffer (CD44v9 1:100; CD44s PanS 1:200) for 30 
minutes on ice. Cells were washed and were incubated with secondary 
antibodies (α-mouse and α-rat Alexa Fluor® 488 1:200, Invitrogen, Eugene, OR) 
for CD44s PanS or CD44v9, respectively, for 30 minutes on ice. Finally, the cells 
were fixed with 2% PFA for 30 minutes at room temperature (RT), centrifuged 
and ressuspended in FACS buffer for analysis by flow cytometry. For the fixation 
and permeabilization protocol, cells were first fixed, permeabilized with 0.5% 
Saponine (Sigma-Aldrich) diluted in PBS for 10 minutes at RT, and stained with 
primary and secondary antibodies diluted in 0.5% Saponine/PBS. Cells were 
ressuspended in FACS buffer for analysis. After the staining cells were analyzed 
in a FACS Canto II using the FACSDiva software (BD Biosciences, San Jose, CA). 
Cells were interrogated for APC-Cy7 using a 633 nm laser and a 780/60 band-
pass filter and for Alexa Fluor® 488 using a 488 nm laser and a 530/30 band-pass 
filter. Data were analyzed using FlowJo software version vX.10.0. (Tree Star Inc, 
USA). For the MFI differences, t-tests were done. All the data were analyzed 
using the GraphPad Prism 6 software (GraphPad Software). Results were 
considered statistically significant with p<0.05. Results shown in Figures 17 and 
20 are from a n = 2 independent experiments (for MKN45 WT and SC) or n = 1 
(MKN45 MOCK and ST6GalNAc I). 
 
3.9 RNA EXTRACTION, cDNA SYNTHESIS AND PCR REACTION 
 Complementary DNA (cDNA) is DNA synthesized from a single-
stranded RNA template, like messenger RNA (mRNA), in a reaction catalyzed 
by the enzyme reverse transcriptase [148].  
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 Polymerase chain reaction (PCR) is a common method used to 
exponentially amplify a specific nucleic acid sequence, generating thousands to 
millions of more copies of that particular DNA segment [149].  
 Cell lines (MKN45 WT/SC, MKN45 Mock/ST6GalNAc I, RKO and LS-
174-T) were grown in 6 well plates and washed with ice cold PBS 1x. 500 μl of 
TRI Reagent (guanidine thioacyanate and phenol; Sigma-Aldrich) were added in 
order to lyse the cells and dissolve DNA, RNA and proteins. After being 
completely detached, cells were transferred to eppendorfs, 100 μl of chloroform 
was added and rested for 15 minutes on ice, to promote the separation of the 
phases. Cellular extracts were centrifuged for 15 minutes at 12000 g at 4 °C, the 
aqueous phase was transferred to a clean eppendorf, 250 μl of isopropanol was 
added and the samples were set to rest 10 minutes on ice (or stored at -80 °C until 
the protocol is resumed). RNA extracts were centrifuged 10 minutes at 12000 g / 
4 °C, the supernatant discarded, and the pellet ressuspended in 800 μl of ice-cold 
ethanol 100%. The centrifugation processes were repeated, and the pellet 
ressuspended in 500 μl of ice-cold ethanol 75%, in order to rehydrate the sample. 
After one last centrifugation, the supernatant was removed, and the pellet was 
left to dry for 30 minutes. Afterwards, the pellet was ressuspended in ultrapure 
H2O (nuclease free water, Ambion®) and quantified using a Nanodrop 1000 UV-
Vis Spectrophotometer system (Thermo Scientific) and stored at -80 °C. 
 Total RNA from cellular samples was transcribed into complementary 
DNA (cDNA) using 2000 ng of RNA. RNA was diluted in nuclease free H2O, and 
1 µl of random primers (50 µM, Thermo Scientific) and 1 µl of deoxynucleotides 
(dNTPs, NZY Tech) (10 mM) were added, in a total of 11 µl. In the T100TM Thermo 
Cycler (Bio-Rad), the samples were heated at 65 °C for 5 minutes, followed by 1 
minute on ice. Afterwards, 4 µl of 5x SSIV buffer, 1 µl of DTT reagent (100 mM), 




1 µl  of RNase OUT recombinant RNase Inhibitor (40 U/µl) and 1 µl of 
SuperScript® IV Reverse Transcriptase (200 U/µl; Invitrogen) were added to a 
reaction tube, briefly centrifuged to mix the components 7 µl of this reaction mix 
were added to each solution containing the annealed RNA. The samples were 
subjected to PCR on the T100TM Thermo Cycler (23 °C x 10 min, 52 °C x 20 min, 
80 °C x 10 min, 4 °C x ∞; Bio-Rad). 
 To perform the PCR, cDNA is amplified using gene-specific primers to 
generate many copies of that specific DNA sequence. For the PCR reaction mix 
preparation, 2 µl of 10x reaction buffer for supreme NZYTaq polymerase (NZY 
Tech), 0.6 µl of MgCl2 (50 mM, NZY Tech), 0.4 µl of dNTPs (10 mM), 0.5 µl of 
Forward Primer (10 µM) (Table 2), 0.5 µl of Reverse Primer (10 µM), 0.2 µl of 
supreme NZYTaq II DNA polymerase (500 U; nzytech) and 14,8 µl of nuclease-
free H2O were added to 1 µl of cDNA from each cell line, in a total of 20 µl. PCR 
reaction was performed in a T100™ Thermal Cycler (Bio-Rad) following the 
program: 94 °C for 5 minutes during 1 cycle (initialization); 94 °C for 30 seconds 
(denaturation), 55 °C for 60 seconds (annealing), 72 °C for 75 seconds 
(elongation), during 34 cycles; 72 °C for 10 minutes during 1 cycle (final 
elongation) and 4 °C for an indefinite time (final hold). Samples were run in a 
1.5% agarose gel and the DNA bands were visualized in a Molecular Imager® 
(Gel Doc™ XR+ Imaging System, Bio-Rad). Relative quantification was 
determined using the Image Lab software (Biorad). All primers were ordered 









Primer designation Primer sequence 5’ to 3’ Expected amplicon size (bp) 









































Table 2. Probes used in PCR for the amplification of sequences of interest. Adapted from [150]. 









v9 forward GCTTCTCTACATCACATGAAGG v9 - Exon 16 
v92: 203 
v9+v103: 407 
v10 forward AGGAATGATGTCACAGGTGG v10 - Exon 16 
v102: 335 
Exon 16 reverse ATTTGGGGTGTCCTTATAGG  
1 No inclusion of variant exon 
2 Inclusion of single variant exon 




 Immunohistochemistry (IHC) is a common microscopy-based technique 
that uses specific antibodies that labeled an antigen target in cells of a tissue 
section. 
 Data from 18 patients treated in the University Hospital São João and IPO-
Porto, between 1990 and 1994 with GC diagnosis and submitted to surgical 
treatment was collected prospectively and their use approved by the local Ethical 
committees. The data collected from clinical examinations included: age, gender, 
gastric tumor classification, sinus histology, follicular hyperplasia and Ming 
classification. Expression of CD44v9, Tn and STn was evaluated in 12 cases of 
human gastric carcinomas (10 intestinal, 5 diffuse sub-type and 3 atypical) [18] 
and CD44v9 immunohistochemical expression was correlated with the available 
clinicopathological data. Additionally, the histological patterns of CD44v9 
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immunohistochemical expression were evaluated in 6 cases of normal adjacent 
tissue of gastric cancer patients. 
 Data from 312 patients treated in the Braga Hospital, between 2005 and 
2010 with CRC diagnosis and submitted to surgical treatment was collected 
prospectively. The data collected from clinical and preoperative diagnostic 
examinations included: age, gender, clinical presentation, oncologic history, 
tumor localization, histological type, macroscopic appearance and preoperative 
staging. The tumor localization was recorded and classified as colon and rectum 
(between anal verge and 15 cm at rigid rectoscopy). Histopathological reports 
included: tumor differentiation, lymphatic and blood vessel invasion, tumor 
staging and recurrence. The level of positive lymph nodes was not described in 
all specimens. The histological type of CRC was determined by two experienced 
pathologists. A series of formal-fixed, paraffin-embedded tissues from these 
patients was analyzed by immunohistochemistry for CD44v9 expression. Slides 
from all 312 specimens were reviewed and mapped and tissue microarrays 
(TMA) were built using a manual tissue arrayer (MTA-1 Beecher Instrument, 
Silver Spring, MD, USA). Representative areas of the CRC lesions were selected 
and cores of 1.0 mm in diameter were twice sampled and arranged at 0.3 mm 
from each other in the recipient paraffin block. A database was built for every 
block produced, including the coordinates of each core and case of origin. 
Comparison of expression in tumor versus normal cells was also possible since, 
in most cases, the same paraffin section contained both neoplastic and normal 
colonic epithelium. CD44v9 immunohistochemical expression was correlated 
with the available clinicopathological data.  
 Immunostaining was performed by the modified avidin-biotin-




xylene, rehydrated with a gradual decreasing concentration of ethanol (100%-
70%) and washed with water. For CD44v9 staining only, heat-induced antigen 
retrieval was carried out in sodium citrate buffer (10 mM citric acid, pH 6.0) for 
40 minutes in a steam cooker (Ufesa), left to cool for 10 minutes at RT and washed 
with PBS 1x. Sections were then treated with 10 % hydrogen peroxide (H2O2) in 
methanol for 10 minutes to block the endogenous peroxidase activity. After 
washing the slides in PBS 1x, sections were incubated with rabbit serum 1:5 
diluted in PBS 10% bovine serum albumin (BSA) in a humid chamber for 30 
minutes at RT. The tissues were incubated with primary antibodies to CD44v9 
(1:500 diluted in PBS 5% BSA) or Tn and STn (undiluted) at 4 °C in a humid 
chamber, overnight. After three washing steps with PBS 1x, sections for 
immunohistochemistry were incubated with biotin-labelled secondary rabbit 
anti-rat (CD44v9) or rabbit anti-mouse (Tn and STn) (DAKO) diluted 1:200 in PBS 
5% BSA, for 30 minutes at RT and with ABC kit (Vectastain®, Vector 
Laboratories) for 30 minutes at RT. After three washing steps with PBS 1x, 
sections were stained for 2-3 minutes with 0.05% 3,3 diaminobenzidine 
tetrahydrochloride (DAB) containing 0.01% H2O2. Finally, sections were 
counterstained with Mayers’ haematoxylin solution, washed with water, 
dehydrated with a gradual increasing concentration of ethanol (70% - 100%) and 
xylol, and mounted. Negative controls were performed by substitution of the 
primary antibody with PBS 5% BSA. Slides were examined and images acquired 


















4.1 GASTRIC AND COLORECTAL CANCER TISSUES 
IMMUNOHISTOCHEMICAL CHARACTERIZATION 
 
Gastric cancer tissues  
 Gastric cancer tissue sections from a total of 12 patients were used to 
perform a preliminary immunohistochemical (IHC) analysis of the in situ 
expression of CD44v9. The cohort characteristics are described in Table 3, 
according to CD44v9 expression. All the histological parameter classification was 
done by a certified pathologist. Histological analysis was performed to 
discriminate samples in their tumor classification, both for the Lauren 
parameters and the newly identified ones [18, 23]; sinus histology; presence of 











4.2 CD44v DIFFERENTIAL CHARACTERIZATION IN GASTROINTESTINAL 




their growth pattern. There were no significant differences in the CD44v9 
expression among these parameters, which is expected given the small number 
of cases of this series (Table 3). With the expansion of the series it is important to 
further test some of the potential trends. 
Table 3. Assessment of associations between CD44v9 expression and clinical data in primary 













   
 Male 7 3 (42.9) 4 (57.1) 0.575 
 Female 5 1 (20.0) 4 (80.0)  
      
Age (Years)     
 ≤ 45 1 0 (0.0) 1 (100.0) 1.000 
 > 45 11 4 (36.4) 7 (63.6)  
  
 
   
Lauren Classification    
 Diffuse 3 1 (33.3) 2 (66.7) 0.851 
 Intestinal 7 2 (28.6) 5 (71.4)  
 Atypical  2 1 (50.0) 1 (50.0)  
  
 
   
New Classification 
 
   
 Glandular 6 3 (50.0) 3 (50.0) 0.545 
 Mix 6 1 (16.7) 5 (83.3)  
      
Sinus Histology 
 
   
 minimum/absent 9 4 (44.4) 5 (55.6) 0.490 
 abundant/moderate 3 0 (0.0) 3 (100.0)  
      
Follicular hyperplasia    
 minimum/absent 1 1 (100.0) 0 (0.0) 0.333 
 abundant/moderate 11 3 (27.3) 8 (72.7)  
      
Ming Classification     
 expanding growth pattern 5 1 (20.0) 4 (80.0) 0.575 
  infiltrating growth pattern 7 3 (42.9) 4 (57.1)   
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 One of the main goals of the work presented in this thesis was to assess 
the relationship of CD44v9 expression to a glycoprofile of truncated O-glycans. 
Therefore, the co-expression profile of the isoform and the Tn and STn structures 
was assessed. Co-expression of CD44v9 and both O-glycan structures did not 
show a statistically significant association. However, co-expression with STn 
showed a p-value of 0.091, possibly indicating a trend (Table 4). 
Table 4. Assessment of associations between co-expression of CD44v9 and the O-glycan Tn and 
STn antigens in gastric tumor cases. 
 













         
negative 4 1 (25.0) 3 (75.0) 0.333 
 4 2 (50.0) 2 (50.0) 0.091 
positive 8 0 (0.0) 8 (100.0) 
  8 0 (0.0) 8 (100.0)  
  
 To further detail the co-existence of CD44v9 and a glycoprofile featuring 
truncated O-glycans, the co-localization patterns of the isoform and the Tn and 
STn structures expression was analyzed (Figure 9). Sequential slides were used 
to perform the three staining protocols and the degree of co-localization was 
classified independently by trained researchers. The results showed several co-
localization profiles (Figure 9 A). In fact, a moderate/high colocalization between 
CD44v9 and Tn was observed in 75% (6 out of 8) of the cases (Figure 9 B). 
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 Interestingly, on normal adjacent tissue (NAT) of some sections, NAT 
samples showed CD44v9 expression in a specific pattern, limited to a frontline of 
linearly connected cells. The histological profile points to CD44v9 expression in 
a tumor basal membrane-like or CD44+ stem cell manner (Figure 10). 
Figure 9. Co-localization of CD44v9 and the truncated O-glycan Tn and STn antigens in gastric cancer 
samples. (A) Representative immunohistochemical co-localized expression of CD44v9 and the Tn and 
STn antigens in the same cases of GC (x 80 and x 200 magnification). (B) Statistical analysis of the co-
localization of CD44v9 and the Tn antigen. (C) Statistical analysis of the co-localization of CD44v9 and 
the STn antigen. 
A 
B C 







Colorectal cancer tissues  
 The malignant function of CD44v9 was also observed in CRC-focused 
studies [54, 78]. Therefore, samples from 312 cases of CRC from the Braga 
Hospital were organized in tumor TMAs, and the expression of CD44v9 was 
evaluated. The cohort characteristics are described in Table 5, such as gender, 
age, tumor presentation and others. The majority of tumors were localized in the 
colon and most subjects were negative for familial history of CRC (Table 5).  
Figure 10. Immunohistochemical expression of CD44v9 in gastric cancer normal adjacent tissue 
samples (original magnification x 50). 
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Table 5. Assessment of associations between CD44v9 expression and clinical data in primary 






p value Negative/weak (%) Moderate/strong (%) 
Gender 
 
   
 Male 194 135 (69.6) 59 (30.4) 0.320 
 Female 118 75 (63.6) 43 (36.4)  
      
Age (Years)  
 
   
 ≤ 45 15 11 (73.3) 4 (26.7) 0.781 
 > 45 297 199 (67.0) 98 (33.0)        
Presentation  
 
   
 Asymptomatic 59 39 (66.1) 20 (33.9) 0.878 
 Symptomatic 253 171 (67.6) 82 (32.4)        
Localization  
 
   
 Colon 236 158 (66.9) 78 (33.1) 0.889 




   
 Polyploid 157 102 (65.0) 55 (35.0) 0.310 
 Ulcerative 67 45 (67.2) 22 (32.8)  
 Infiltrative 35 27 (77.1) 8 (22.9)  
 Exophytic 21 17 (81.0) 4 (19.0)  
  
 
   
Familiar history 
of CRC  
 
   
 Negative 256 171 (66.8) 85 (33.2) 0.825 
 Positive 25 16 (64.0) 9 (36.0)        
CEA (ng/mL)  
 
   
 ≤ 10 214 139 (65.0) 75 (35.0) 0.437 
  > 10 48 34 (70.8) 14 (29.2)   
  
 The samples were classified into CD44v9 negative/weak and 
moderate/strong expression. Moreover, the results from the IHC protocol to 
detect CD44v9 were matched with histological and clinical parameters, and 
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associations were analyzed (Figure 11 and Table 6). There was a statistically 
significant association (p-value = 0.023) between the tumor size and CD44v9 
expression, with higher percentage of CD44v9 cases in larger tumors. 
Histological type, differentiation degree, lymphatic invasion and cancer 
recurrence did not show any association with CD44v9 presence. Vessel invasion 
showed a close to significant association (p-value = 0.132), where CD44v9 
positive malignancies present lower levels of vascular structures within the 
tumor. Although not statistically significant, there seems to be a trend with tumor 









Table 6. Assessment of associations between CD44v9 expression and pathological data in 





Tumor cells P 
value Negative/weak (%) Moderate/strong (%) 
Tumor size (cm) 
 
   
 ≤ 4.5 179 129 (72.1) 50 (27.9) 0.023* 
 > 4.5 115 68 (59.1) 47 (40.9)  
  
 
   
Figure 11. Representative immunohistochemical expression of CD44v9 in colorectal cancer TMA 
samples (original magnification x 200). 
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 Adenocarcinoma 281 188 (66.9) 93 (33.1) 0.477 
 A. Mucinous 28 19 (67.9) 9 (32.1)  
 Signet ring and mucinous 3 3 (100.0) 0 (0.0)  
  
 
   
Differentiation     
 Well/moderate 272 186 (68.4) 86 (31.6) 0.422 
 Poorly/Undifferentiated 33 19 (57.6) 14 (42.4)  
      
Stage      
 0 2 2 (100.0) 0 (0.0) 0.437 
 1 48 36 (75.0) 12 (25.0)  
 2 118 79 (66.9) 39 (33.1)  
 3 99 65 (65.7) 34 (34.3)  
 4 41 24 (58.5) 17 (41.5)  
      
Lymphatic invasion 
 
   
 Absent 133 87 (65.4) 46 (34.6) 0.617 
 Present 159 109 (68.6) 50 (31.4)  
  
 
   
Vessel invasion 
 
   
 Absent 173 111 (64.2) 62 (35.8) 0.132 
 Present 126 92 (73.0) 34 (27.0)  
      
Recurrence  
 
   
 No 266 179 (67.3) 87 (32.7) 1.000 
 Yes 46 31 (67.4) 15 (32.6)  
 
4.2 CD44v DIFFERENTIAL CHARACTERIZATION IN 
GASTROINTESTINAL CANCER CELL LINES EXPRESSING 
TRUNCATED O-GLYCANS 
 
 To explore potential alterations of CD44 protein regulation in cells with 
O-glycosylation truncation, previously established cell line models were used. 
The MKN45 (diffuse type gastric carcinoma) and the AGS (intestinal type gastric 
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carcinoma) isogenic SimpleCell models were developed using ZFNs to disrupt 
COSMC [119, 135]. In addition, MKN45 were stably transfected with a 
ST6GalNAc-I overexpressing plasmid (MKN45 ST6GalNAc I cells) and a mock 
control (MKN45 MOCK cells), giving rise to an alternate O-glycan truncation 
model [131]. Cells were cultured in coverslips and the expression of truncated O-
glycans was evaluated in these models by immunofluorescence. The 1E3 
monoclonal antibody, targeting the Tn structure, and the B72.3 targeting the STn 
(Figure 12) were used. As expected, IFs showed positive signal for Tn and STn in 
the SC models, with more intensity than the control counterparts, where the 
signal was absent or low for both structures. The RKO cell line (colon carcinoma) 
was also evaluated for the presence of Tn and STn and found to have absent or 
low expression of both. 
 The same set of cells was submitted to IF protocols for two CD44 isoforms: 
CD44s and CD44v9. The monoclonal antibody 2C5 clone was used to detect 
CD44s and the RV3 for CD44v9. According to the manufacturer, the 2C5 clone 
recognizes an epitope in the invariant N-terminal region of CD44, present in all 
CD44 isoforms, with higher affinity to CD44s [142]. The RV3 clone recognizes the 
peptide sequence of the v9 exon, that may be present in several isoforms 
(CD44v3-10 or CD44v8-10, for instance). Immunofluorescence analysis revealed 
all the MKN45 cell models, WT, SC, MOCK and ST6GalNAc I, had expression of 
CD44s and CD44v9. In contrast, none of the isoforms tested was detected in AGS 
models. The most intense signal for CD44s was seen in RKO cells, that in turn 
show no CD44v9 expression (Figure 13). 
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Figure 12. Immunofluorescence analysis of Tn and STn antigens expression in GC (MKN45 and AGS) 
and CRC (RKO) cancer cell lines. Nuclei are shown in blue and O-glycan structures in green. The scale 
bar corresponds to 50 μm. 






















































































Figure 13. Immunofluorescence analysis of CD44s PanS and CD44v9 expression in GC (MKN45 and 
AGS) and CRC (RKO) cancer cell lines. Nuclei are shown in blue and CD44 isoforms in green. The 
scale bar corresponds to 50 μm. 
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 With the CD44s and CD44v9 expression first assessed by IF, protein 
extracts were made and Western blot analysis was done to detect protein levels 
of total CD44, CD44s and CD44v9 (Figure 14). The monoclonal antibody that was 
used to recognize total CD44 was the clone that detects all CD44 protein isoforms. 
The expression profiles revealed that MKN45 WT cells express high levels of total 
CD44 and CD44s, whereas the presence of CD44v9 was weakly detected. The SC 
model expressed total CD44 at levels below 20% of the WT cells (Figure 14 A), 
and no CD44s (Figure 14 B), but expressed an average of 3-fold higher protein 
amounts of CD44v9 (Figure 14 C). Interestingly, there were no significant 
differences between the MOCK and ST6GalNAc I cells expression profiles of 
tested CD44 variants, although there is a tendency for increased CD44v9 
expression in the ST6GalNAc I models (Figure 14 C). The WB analysis enables 
the interpretation of the molecular weights of the protein isoforms detected. Both 
the WT and MOCK total CD44 proteins are detected between 150 and 250 kDa, 
whereas in the SC there is a discrete band bellow 150 kDa, and an enrichment of 
total CD44 in the 150 kDa range in the ST6GalNAc I model (Figure 14 A). The 
same profile is detected for CD44s, except for the SC model, that shows no CD44s 
protein expression, as mentioned. Focusing in the CD44v9 blot, again the WT and 
MOCK show similar expression profiles. In the SC, CD44v9 is predominantly 
detected at the same molecular weight as total CD44 and in the ST6GalNAc I 
there is an enrichment of protein in the same molecular weight, but larger 



























 The intriguing results regarding the different immunoreactivity of the 
MAbs used as evaluated in IF and WB analysis, led to further investigate their 
reactivity in these models. Most commercial MAbs, including MAbs to CD44 
variants, are raised by non-glycosylated recombinant proteins and, hence, there’s 
the possibility that glycosylation could result in both altered CD44v protein 
conformation and masking of specific proteins on the peptide backbone. 
Figure 14. Western blot analysis of total CD44 and isoforms in protein extracts from gastric cancer cell 
line models of O-glycan truncation (MKN45 SC, AGS SC, MKN45 ST6GalNAc I) and their control 
counterparts (MKN45 WT, AGS WT and MKN45 MOCK). (A) Total CD44 protein detection and 
relative quantification. (B) CD44s PanS protein detection and relative quantification. (C) CD44v9 
protein detection and relative quantification. For quantifications, the intensity of all protein bands 
was normalized to tubulin and MKN45 WT cell line.  * indicates p-value <0.0500, ** <0.00500, **** 
<0.00005. 
C  A B 
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 Since WT cells showed CD44s and CD44v9 expression in the IF assays, but 
significantly reduced protein presence in the WB, when compared to the SC 
model, deglycosylation assays were employed on the protein extracts, to 
evaluate whether the elongated glycans in the WT proteins could interfere with 
CD44 isoforms detection. Protein extracts were incubated with deglycosylation 
enzyme mixes, which included neuraminidase, PNGase F and a commercial 









Figure 15. Impact of deglycosylation treatment in CD44v9 detection in protein extracts from 
colorectal cancer (RKO) and gastric cancer cell line models (MKN45 WT and SC). (A) Western blot 
analysis of CD44v9 detection after treatment with neuraminidase (Neu), a deglycosylation mix (Mix) 
and PNGase F. (B) Relative quantification of western blot results. Intensity of all protein bands was 
normalized to tubulin and MKN45 WT cell line without deglycosylation treatments. Intensity of the 
band correspondent to MKN45 SC without treatment consists of the mean between the 2 
experiments. 
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 Neuraminidase removes terminal sialic acid molecules in both N- and O-
glycan structures. The PNGase F enzyme cleaves all N-glycans, which are known 
to exist in CD44: 6 sites in the standard protein, 1 in the v5 exon and 2 in the v10 
exon. Finally, the commercial deglycosylation mix contains an enzyme cocktail, 
described in section 3.6, which cleaves the majority of glycan structures. Protein 
extracts from RKO cells were used as a negative control for the CD44v9 
deglycosylation assays, since this cell line shows CD44s but no CD44v9 
expression. In the MKN45 WT extracts the CD44v9 detection was not improved 
by any of the treatments, nor the shift in the molecular weight of the CD44v9 
band. The removal of glycan structures should generate detection at a lower 
molecular weight. For the SC extracts it was observed a shift in molecular weight 
for all mixes, which indicated that the CD44v9 protein, in these cells, maintains 
N-glycosylation structures, and terminal sialic acids (presumably in the STn 
glycan and N-glycans). 
 As it was previously mentioned, the CD44 receptor is heavily O-
glycosylated thanks to its mucin-like repeats in the variable region. In MKN45 
WT background these O-glycan structures are complex and elongated. In CD44v 
the degree of glycosylation is increased as extra glycosylation sites are provided 
by additional inserted exon products. All together, in MKN45 WT, CD44 is 
expected to have a high molecular weight, that can interfere in technical aspects 
of the WB method, such as, the gel electrophoresis (entrance in the gel, for 
instance) and transfer.  
 To exclude this hypothesis, dot blotting analysis was performed. Dot blots 
are simplified protocols of WBs with the exception that the proteins to be 
detected were not separated according to its molecular weight in an 
electrophoresis step, nor transferred to a membrane from a polyacrylamide gel. 
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Instead, protein extracts are loaded directly to the membrane and detection is 
performed. For this, MKN45 WT and SC extracts were used, as well as AGS WT 
and SC (as a negative control) and MKN45 MOCK and ST6GalNAc I. The 
detection of the STn glycan was used as an internal experimental control. The 
results showed STn expression for both SC models and for ST6GalNAc I cells. 
The detection of total CD44, CD44s and CD44v9 followed the pattern of the WBs 





 Since the IF gave conflicting results with WB and Dot Blot analysis 
regarding CD44v9 protein expression and CD44s presence in the O-glycan 
truncation models, flow cytometry analysis was done for both membrane and 
total CD44s and CD44v9. Cells were stained and fixed for the analysis of the 
membrane protein and fixed, permeabilized and stained for the analysis of the 
membrane and intracellular fractions. Permeabilization was done with Saponin, 
which enables the formation of pores in the membrane, so detection antibodies 
Figure 16. Dot blot analysis of STn antigen, total CD44, CD44s PanS and CD44v9 isoform in protein 
extracts from gastric cancer cell line models of O-glycan truncation (MKN45 SC, AGS SC, MKN45 
ST6GalNAc I) and their control counterparts (MKN45 WT, AGS WT and MKN45 MOCK). 
CHAPTER 4. RESULTS 
66 
 
can enter the cytoplasm (Figure 17 A). Since the permeabilization with this 
method is transient, the same Saponin concentration was maintained during the 





















 The MNK45 WT cells showed more heterogenous and reduced levels of 
membrane CD44v9 expression when compared to the SC model, given by the 
A 
B C 
Figure 17. Flow cytometry analysis of CD44v9 and CD44s PanS isoforms expression in gastric cancer cell 
line models of O-glycan truncation (MKN45 SC and MKN45 ST6GalNAc I) and their control counterparts 
(MKN45 WT and MKN45 MOCK). (A) Schematic representation of staining protocols: surface fraction 
(left) and both surface and intracellular fractions (right). (B) Histograms of CD44v9 fluorescence signal of 
used cell lines and respective negative controls (top) and relative MFI quantification (bottom). (C) 
Histograms of CD44s PanS fluorescence signal of used cell lines and respective negative controls (top) 
and relative MFI quantification (bottom). All MFI values were subtracted the negative control intensity 
and normalized to the MKN45 WT cell line. 
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mean fluorescence intensity (MFI) of the antibody (Figure 17 B, top left histogram 
and bottom left graph). There were no differences between the MOCK and 
ST6GalNAc CD44v9 membrane expression profiles (Figure 17 B, bottom left 
histogram and bottom left graph). When the detection of intracellular CD44v9 
was enabled, there was no significant differences between any of the models, 
indicating differential distributions of the protein in the SC model (Figure 17 B, 
right histograms and bottom right graph). Regarding CD44s, the SC model tends 
to an increased membrane CD44s, compared to the WT cells, and there are no 
differences between MOCK and St6GalNAc I (Figure 17 C, left histograms and 
bottom left graph). The total protein staining revealed that there were no 
differences between the models, regarding CD44s protein presence (Figure 17 C, 
right histograms and bottom right graph). 
 The final analysis made was on the relative CD44 mRNA isoforms 
expressed in the cell lines used. Primers were designed so specific variants would 
be amplified on the cDNA from total RNA extracts. The PCR reactions had an 
exon/variant specific forward primer and a common reverse primer targeting 
exon 16 (present in all isoforms) (Table 1). In total, 10 different forward primers 
were used. The MKN45 WT, SC, MOCK and ST6GalNAc RNA was used, as well 
as RNA from RKO and LS-174T cells. The LS-174T cell line is derived from CRC 
and has a genetically dual population in bulk: COSMC+/+ or COSMC-/- [152].  
 The PCR products for the several isoforms were separated according to 
the molecular weight in an agarose gel electrophoresis and the band sizes were 
matched with in silico analysis of the mRNA sizes, after alternative splicing 
(Table 1). The PCR for exon 3 was designed to amplify all the isoforms in the 
RNA extracts, since it had forward and reverse primers targeting the two 
standard regions of the CD44 transcript (Figure 18). 















 The CD44v8-10 was the predominant isoform in the MKN45 cell line 
models, with relative presences ranging from 58 to 77% of the total transcript 
(Figure 18 B and C). The CD44s was the 2nd most expressed isoform in the MKN45 
cells, with larger presence for the MOCK and ST6GalNAc I models (Figure 18 B 
and C). LS-174T followed a similar expression pattern than the MKN45 cells, 
whereas the RKO cells expressed 93% of the CD44s isoform, which was according 
to the strong IF signal already observed in Figure 13 (Figure 18 B and C). 
 To increase sensitivity of the assay, other primers were used to further 
dissect isoform expression (Figure 19). The SC model stood out from the other 
MKN45 cell lines in the increased expression of the CD44v3-10 and CD44v5-10 
transcripts (Figure 19 A and B). The LS-174T cell line revealed itself similar to 
MKN45 in the other variants’ expression (Figure 19). The differences on RKO 
variants’ expression continued to be detected. These cells expressed higher levels 
of the single exon variants CD44v3, CD44v5 and CD44v6 (Figure 19 A, B and C). 
A B 
C 
Figure 18. CD44 mRNA levels of GC cell lines, MKN45 WT (WT), MKN45 SC (SC), MKN45 MOCK (M6) 
and MKN45 ST6GalNAc I (ST6), and CRC cell lines, RKO and LS-174T. (A) Analysis of the total set of 
CD44 isoforms expressed in the different cell lines. (B) Percentage of detected variants expression, 
relative to the total PCR products of each cell line.  (C) Schematic representation of three main CD44 
isoforms (left) and respective percentage of relative expression for the different cell lines (right). 
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 Figure 19. CD44 mRNA levels of GC cell lines, MKN45 WT (WT), MKN45 SC (SC), MKN45 MOCK 
(M6) and MKN45 ST6GalNAc I (ST6), and CRC cell lines, RKO and LS-174T, using different variant 
specific forward primers: (A) v3; (B) v5; (C) v6; (D) v8; (E) v9; (F) v10. Percentage of detected variants 
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4.3 CD44v EXTRACELLULAR CLEAVAGE AND ITS 
RELATIONSHIP WITH O-GLYCAN TRUNCATION 
 
 CD44 proteolytic cleavage at its extracellular region is known to have 
biological implications in the regulation of the CD44 dependent cell-matrix 
interaction and signaling pathways [58]. As it was mentioned, O-glycan 
truncation was shown to increase total CD44 surface cleavage [139], but there 
was missing knowledge about specific isoforms. 
 The cell lines used in the work of this thesis are adherent cells and their 
detachment from culture flasks is required for their maintenance and to place 
cells in a single-cell suspension for flow cytometry analysis. The detachment 
protocol is based on the disruption of cell-cell and cell-flask adhesion linkages, 
either by chelator agents (that remove ions that mediate interactions) or 
proteolytic cleavage of the adhesion proteins. For the flow cytometry analysis 
showed in Figure 17, Versene, a commercial chelator agent was used, to preserve 
surface protein integrity. To test the sensitivity of CD44 variants against 
extracellular proteases, the CD44v9 and CD44s presence was assessed by flow 
cytometry comparing the detachment of cells using either Versene or Trypsin. In 
the cells treated with Trypsin, the levels of surface CD44v9 detection was 
reduced to 50% in the MKN45 WT, whereas in the SC was decreased to 5%.  For 
the MOCK and ST6GalNAc I cells the results were similar, showing reduction to 
20-30% in the Trypsin condition. The reduction in the Trypsin-treated cells had 
fewer extend when both surface and intracellular fraction were analyzed (Figure 
20 A). When the CD44s was probed in the Trypsin-treated cells there was a 
reduction of 2-fold in fluorescent signal for the MKN45 WT cells. Interestingly, 
CD44s was not detected with these conditions in the SC model. There was a small 




reduction in the MFI signal for the MOCK and ST6GalNAc I cells (Figure 20 B). 
When the cells were permeabilized prior to staining, there was no alteration for 
the WT cells and CD44s was detected in the SC model. The MOCK and 
ST6GalNAc I cells showed reduction of total (surface and intracellular) CD44s 



















 The Trypsin-resistance results indicated that CD44 variants sensitivity to 
proteases could be altered in the genetic background responsible for the 
Figure 20. Flow cytometry analysis of CD44v9 and CD44s PanS isoforms expression in gastric cancer 
cell line models of O-glycan truncation (MKN45 SC and MKN45 ST6GalNAc I) and their control 
counterparts (MKN45 WT and MKN45 MOCK), after detachment using Trypsin. (A) Histograms of 
CD44v9 fluorescence signal of used cell lines and respective negative controls (top) and relative MFI 
quantification compared to Versene (bottom). (B) Histograms of CD44s PanS fluorescence signal of 
used cell lines and respective negative controls (top) and relative MFI quantification compared to 
Versene (bottom). All MFI values were subtracted the negative control intensity and normalized to 
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generation of glycoprofiles enriched with immature structures. The presence of 
cleaved total CD44, CD44v9 and CD44s were assessed by WB of the protein 
extracts of the cells and the culture media (Figure 21 A). This protocol involved 
the culture of cells in FBS-free media for 48 hours and the removal of proteins 
bellow 10 kDa. As it was mentioned, the WB analysis enables the detection of the 
molecular weights of the proteins, relevant for cleavage experiments, since the 
cleaved protein is always smaller than the intact one. The band intensity was 
normalized to the total Ponceau staining. The relative protein presence, 
compared to the extract of MKN45 WT cells, was analyzed. The ST6GalNAc I 
showed increased cleavage of total CD44 and CD44s. For the CD44v9 cleavage, 
the SC and the ST6GalNAc cells showed a 4-fold increase in CD44v9 media 














Figure 21. Comparative western blot analysis of total CD44 and isoforms and tubulin in total protein 
extracts and in conditioned medium (secretome), from gastric cancer cell line models of O-glycan 
truncation (MKN45 SC, AGS SC, MKN45 ST6GalNAc I) and their control counterparts (MKN45 WT, 
AGS WT and MKN45 MOCK). (A) Total CD44 protein detection and relative quantification. (B) CD44s 
PanS protein detection and relative quantification. (C) CD44v9 protein detection and relative 
quantification. For quantifications, the intensity of all protein bands was normalized to the total 
Ponceau staining and MKN45 WT cell line. 

















GENERAL DISCUSSION  
 
 CD44 is one of the most variable surface molecules, in terms of function 
and structure. Alternative splicing, often altered in cancer cells [56], generates a 
vast repertoire of CD44 transcripts that translate into different protein variants, 
containing different profiles of post-translational modifications [55, 58]. CD44 
presence in both GC and CRC has been shown in different cohorts and its variant 
CD44v9 has also deserved attention, being associated with tumor progression 
and aggressiveness [75, 78, 153]. Interestingly, in previous work of the 
Glycobiology in Cancer group, CD44 was identified in the SC model of a gastric 
cancer cell line as a potential secreted biomarker O-glycoprotein with immature 
O-glycans, which was validated in cancer patients’ sera. In the same work, the 
single O-glycosite identified by mass spectrometry in GC patient’s serum was in 
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 In this thesis, tissue samples and cell lines from GI cancers were used to 
characterize the global relationship between CD44v9 and CD44s expression and 
a truncated O-glycoprofile. 
 
I. CD44v9 expression in GI cancer tissues 
 CD44v9 has been shown to have critical roles in GI carcinogenesis [69, 70, 
75, 78, 153] and its presence was evaluated in a GC series of patients available in 
the group. For this, IHC analysis was first performed in tissue samples of the 
target malignancies, GC and CRC. The expression of CD44v9 and the Tn and STn 
structures were assessed in a GC series of patients and associations were 
evaluated. The staining pattern of the targets tested followed what had been 
described for CD44v9 [153] and truncated O-glycans [131]. Interestingly, there is 
a trend of CD44v9 and STn co-expression (p-value = 0.091) in the GC series. 
Although being a small series, all cases with CD44v9 expression showed STn 
presence (Table 3). Moreover, co-localization of Tn and STn with CD44v9 was 
observed for the majority of the cases, suggesting that the CD44v9 proteins 
present in the tissue could be glycosylated with those structures. Proximity 
ligation assays (PLAs) targeting both truncated O-glycans and CD44v9 should 
reveal the veracity of the previous hypothesis. PLA is a technique were the 
distance between two antibody targets is measured, having the sensitivity do 
determine whether CD44v9 is sugar-coated with those glycans structures. In 
previous work, one of the CD44 variants, CD44v6, was also shown to be 
aberrantly glycosylated with the STn glycan in GC tissue sections, by PLA [119]. 
Additionally, CD44 proteins containing the STn structure were detected in both 
GC tissue protein lysates and matching sera. In this case, the higher levels of 





healthy subjects. However, it did not occur for tissue CD44-STn [154]. Therefore, 
the focus on CD44 specific isoform variants combined with cancer-related glycan 
structures could pave the way for new biomarker molecules in GC. The results 
of this thesis present CD44v9 as a potential target. Interestingly, CD44v9 was 
detected in normal adjacent tissue (NAT) of cancer patients. The profile of 
staining resembles the front-line basal membrane of a tumor, previously seen in 
GC samples [153]. Moreover, it could also be the staining of proliferative cells in 
gastric villi, that express normal and elongated O-glycans. Generally, in the 
human gut epithelium, the CD44s, CD44v6 and CD44v4-10 isoforms are found, 
being the last variant expressed usually by intestinal stem cells [155]. The CD44v9 
positive cells in the NAT could be taking part in the regeneration of the gastric 
epithelium. Therefore, their glycoprofile could be a discriminating factor, 
meaning that CD44v9 is not expected to carry STn in non-tumorous cells. To 
elucidate, an IHC analysis for STn, structure that functions as proxy for cancer 
cells, could be performed, clarifying the true identity of CD44v9 expressing cells 
in the NAT. 
 Colorectal TMAs were also used to address the existence and extend of 
CD44v9 expression. Analysis of the CD44v9 profile of detection in the samples 
was performed to investigate any clinical associations. There was a statistically 
significant association of CD44v9 expression and tumor size (Figure 11 and Table 
5). This agrees with the notions that CD44v9 positive tumors are more aggressive. 
In addition, a positive trend is observed (p-value = 0.132) between CD44v9 
expression and the absence of vessel invasion. What can be hypothesized is that 
the presence of CD44v9, which provides resistance to ROS [69], as it was 
discussed in the Introduction, inhibits angiogenesis. Elevated levels of 
intracellular ROS were shown to induce vessel formation through the vascular 
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endothelial growth factor (VEGF) axis [156]. To confirm this, the evaluation of 
VEGF presence could be inversely related with CD44v9. In fact, CD44v9 presence 
could be used as an additional parameter for patient differentiation in anti-VEGF 
targeted therapies in CRC [157]. Moreover, the absence of CD44v9 in stage 0 CRC 
indicates that it is a cancer specific marker. The noteworthy 2-fold increase in 
CD44v9 positive sample percentage within the early stage 1 and the late stage 4 
disease also represents the CD44v9 relationship with cancer progression and 
aggressiveness. Also following this trend in the GC series is the expanding 
growth pattern showed in CD44v9 positive cases (4 out of 5), according to the 
Ming classification. Nevertheless, future work on the expression of Tn and STn 
in the TMAs will be crucial to further investigate the relationship between 
truncated O-glycans and CD44v9.  
 
II. CD44 variants presence characterization in truncated O-glycan models 
 Given these results, it is clear that CD44v9 has a major role in gastric and 
colorectal cancer and that the combination with O-glycan truncation could 
present itself as a novel promising mechanism of malignancy. To dissect these 
mechanisms, alterations in the cancer-related CD44v9 [157] and the ubiquitously 
expressed CD44s [158] isoforms expression were evaluated in truncated O-
glycan models that are described in section 1.4 of the Introduction chapter. Also, 
identification of CD44 isoforms involved in all these processes is possible mainly 
using CD44v specific monoclonal antibodies. The present work assesses the 
immunoreactivity of some of these MAbs. Immunodetection of CD44 could be 
impaired essentially by: (i) post-translational modifications that can mask exon-
specific epitopes, (ii) conformational changes due to both alternative splicing and 





cleavage/shedding. All of these features are cell type specific and thus, likely to 
impact immunodetection, and they were all tested in this work. 
The initial approach was to perform IF analysis of the two target CD44 
variants presence in cultured cells. This analysis gave the preliminary profiles of 
CD44v9 and CD44s expression that guided following work. The AGS cell 
models, being negative for CD44 presence, were further used as a negative 
control. 
Western blot analysis revealed distinct patterns of total CD44, CD44s and 
CD44v9 protein detection. It is known that glycans increase molecular weight. 
Therefore, it would be expected the same profile of molecular weight distribution 
to be shifted to lower sizes for the O-glycan truncation models, given the lack of 
complex elongated structures. This is observed between the MOCK and 
ST6GalNAc I models in the total CD44, CD44s and CD44v9 blots. The shift is 
further seen in the WBs comparing the WT and SC. However, a CD44 sharper 
band was observed in the total CD44 WB in the SC model. This band may 
correspond to a condensation of the CD44 pattern shown in the WT, due to the 
homogeneous profile of the SC cells, composed exclusively of truncated O-
glycans. Additionally, CD44s detection is absent in the SC, which conflicts with 
the IF results. Both WB results for CD44 total and CD44s show that the SC and 
ST6GalNac I models, although being used for the same purpose of O-glycan 
truncation, have distinct glycoprofiles regarding CD44 isoforms detection. 
CD44v9 detection both in WT and MOCK is significantly reduced when 
compared with the correspondent models with truncated O-glycans (Figure 14). 
Since Dot blot analysis validated all WB results, it excludes the possibility of 
technical problems concerning protein electrophoresis and transfer (Figure 16). 
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Therefore, the results could indicate that CD44 variants have differential protein 
regulation in the truncated O-glycan models. 
 Antibodies used in experimental procedures detect protein epitopes that 
can be influenced by post-translational structures, including glycans. IF and WB 
gave conflicting results regarding CD44 isoforms, that could be a product of 
glycan-dependent antibody recognition. Therefore, deglycosylation assays were 
done for CD44v9. In the WT, the deglycosylation treatment did not improve 
CD44v9 detection and the expected size shift towards lower molecular weight 
did not occur. This could be explained by the inefficient removal of O-glycan 
structures. In this experiment, GAGs were not removed because they are 
conserved among cell models and are not expected to influence antibody 
detection. Also, since the N-glycosylation pathway is theoretically unchanged in 
the SC model, the PNGase F treatment should not improve detection in WT 
protein extracts, which is observed. In the SC model, the O-glycans do not 
contribute to the significant increase in molecular weight of CD44, as they are 
truncated. However, the detected band is the same for PNGase F and the 
deglycosylation mix, which further validates that the mix is not properly 
working in its fullest, as it appears to only be removing N-glycans. This is not 
surprising given that the O-glycan structures removal requires a vast repertoire 
of glycosidases, that sequentially remove individual monosaccharides (Figure 
15). In addition, as CD44 is heavily glycosylated, containing 146 predicted sites 
of O-glycosylation [139], it is reasonable to think that the commercial cocktail 
does not provide the efficiency required. On the other hand, N-glycans have a 
conserved structure which enables full removal using a single glycosidase. 
Besides, CD44 only has 9 N-glycosylation sites (6 in CD44s, 1 in CD44v5 and 2 in 





[79, 80]. To further dissect the impact of O-glycosylation elongation in antibody 
recognition, in vitro O-glycosylation inhibition assays should be performed. 
Moreover, those assays would also give insights to CD44s PanS antibody 
detection. 
 The cellular localization of the CD44 variants studied in this thesis could 
give insights on the differences observed on the WB analysis. To achieve this, 
surface and intracellular staining were performed for CD44v9 and CD44s and 
evaluated by flow cytometry (Figure 17). Total CD44 is not included as previous 
published work showed no differences between the cell lines [139]. The SC model 
shows an increase in surface CD44v9, when compared to the WT, that is not 
observed in the total protein staining. This reveals a differential distribution of 
the protein between cell models, with the SC model having elevated CD44v9 
levels at the surface. Also, this can be linked to already described malignant 
features of the SC model [120]. Interestingly, between the MOCK and 
ST6GalNAc I this is not observed, showing that different truncated O-glycans 
profiles have distinct influence in CD44v9 distribution. Regarding CD44s, the SC 
model shows the highest protein expression at the cell surface but the lowest total 
protein presence, which contradicts WB results. 
To assess whether alternative splicing of the CD44 gene transcript is being 
influenced by truncated O-glycans, PCRs where done. What is observed is that 
O-glycan truncation does not interfere with the global CD44 profile of expression 
(Figure 18), given by the comparison of MKN45 WT and MOCK with SC and 
ST6GalNAc I, respectively. Two CRC cell lines were included for the variant 
relative expression evaluation, RKO and LS-174T. LS-174T showed similar 
variant presence compared to MKN45 models. This enables the use of this cell 
line for the validation of the CD44 behavior, described in this thesis, for O-glycan 
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truncation in colorectal cancer. Regarding RKO, the vast majority of CD44 
transcripts corresponds to the standard CD44s isoform, without variant exons, 
whis is in agreement with IF results. 
O-glycan truncation impact on CD44 alternative splicing is observed 
when PCR sensitivity is increased for some specific variants (Figure 19 A-C). 
These specific splicing events could be linked to receptor signaling pathways, 
which are known to be influenced by their glycoprofile, mediating receptor 
clustering and turnover rates [33, 79, 80]. The mainly expressed CD44 isoform 
containing the CD44v9 exon is the CD44v8-10. The relative quantification 
showed that its transcript is not differentially detected between MKN45 cell lines. 
This proves that the CD44v9 distinct behavior that was observed in the previous 
assays can only be explained by post-translational regulation, as opposed to 
alterations in gene transcription.  
 Analyzing all the results obtained in subchapter 4.2, the recognition of 
CD44v9 by monoclonal antibodies revealed to have glycan-variant specific 
dependencies [159]. On the other hand, the CD44s PanS antibody detection 
inconsistencies between the different techniques performed could be attributed 
to a dependency regarding protein conformation, associated to a specific 
glycosylation profile. In fact, SC engineering could, per se, contribute to the 
change in conformation of glycosylated proteins such as CD44. Together with the 
fact that the three-dimensional protein structure was denatured for WB analysis, 
this could explain the lack of CD44s presence in the SC model, but antibody 
recognition when it is used in assays without protein denaturation, like IF or flow 
cytometry. The analysis of the RNA results (Figure 18) for the MKN45 WT, 
MOCK and ST6GalNAc I revealed that the total CD44 protein repertoire is not 





profiles of those cell lines, it reveals the exact same patterns using total CD44 or 
CD44s PanS antibodies. This opens the question of CD44s PanS antibody 
specificity. One approach to clarify the antibody’s target would be to transfect 
CD44 negative cells, AGS cell line for instance, with either CD44s or CD44v8-10 
expression plasmids, and perform a WB analysis for total CD44, CD44s and 
CD44v8-10 proteins. If the staining observed by the CD44s PanS antibody would 
contain any signal in the CD44v8-10-transfected cells, the specificity of the 
antibody could be interrogated. Furthermore, to assess the glycan structures 
influence on recognition, the same experimental setup could be done in the AGS 
SC model. 
 The increased detection of CD44v9 in the SC model could either be 
explained by a more efficient antibody recognition of the receptor containing 
truncated O-glycans, or by an enrichment of the protein in these cells. The 
detection issue will be further dissected in future work, already mentioned, with 
the inhibition of the O-glycosylation pathway. In fact, the CD44v9-specific MAb 
clone RV3 used in this thesis has been applied in GC research. Kodama et al. 
studied the expression of three CD44v in GC tissue samples: CD44s, CD44v6 and 
CD44v9 (using the RV3 clone). The expression of all the CD44 variants at the 
tumor invasive front showed association with prognosis. The expression of 
CD44v9 in the whole tumor, equivalent to the profile observed in the GC series 
presented in this thesis, was the only that showed association with poor survival 
in the cohort studied [160]. Based on the results of section 4.1, the co-expression 
of CD44v9 and Tn or STn evaluation could increase even further the prognostic 
impact of this variant. 
 The other explanation implies a misregulation of CD44v9 dynamics in the 
SC model. Assuming no differences in protein translation between the WT and 
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SC cell lines, the CD44v9 containing isoforms could be more stable in MKN45 SC 
cells. Immature glycans were shown to decrease protein stability and promote 
degradation [33]. However, CD44v9 containing isoforms could be enriched in the 
SC model because they have the highest half-life. Supporting this, when 
intracellular CD44v9, the set of newly translated proteins, is the staining target 
(Figure 17), there are no differences between the models. This hypothesis could 
be demonstrated in assays where protein synthesis and degradation are 
inhibited, with the evaluation of CD44v9 presence in the different models. 
  
III. CD44 variants extracellular cleavage in truncated O-glycans glycoprofiles 
 One of the main post-translational events of the CD44 protein is its 
extracellular cleavage [58]. Using a simple assay, the protease sensitivity of 
CD44v9 and CD44s was evaluated in the presence of truncated O-glycans. 
Trypsin treatment showed a decrease in surface protein detection by flow 
cytometry, for all models. However, for the SC model it was drastic. This 
indicated that O-glycans have an impact on trypsin proteolytical cleavage. 
Elongated and complex O-glycans seem to protect surface proteins from trypsin 
recognition and cleavage, when compared to truncated structures (Figure 20), as 
seen in other work [161]. 
 Additionally, the secretome analysis showed that, whenever the O-
glycosylation pathway was blocked, in the SC and ST6GalNAc I models, the 
secreted/shed CD44v9 detection was promoted, compared to WT or MOCK 
counterparts. Interestingly, only in the SC model, this was not observed for the 
total CD44, neither for CD44s, as it was for ST6GalNAc I cells, where all CD44 
proteins tested had higher secreted fractions. Once again, SC and ST6GalNAc I 





rates of CD44ecd in immature O-glycan composed glycoprofiles, which leads to 
the release of the CD44icd from the membrane and consequential translocation 
to the nucleus. Nuclear CD44icd can associate with transcription complexes and 
activate the transcription of several genes [58]. Interestingly, CD44icd-depedent 
gene activation shares many of the targets of the hypoxia-inducible factor-1alpha 
(HIF1a) transcription factor [162]. Cell viability and growth in hypoxic conditions 
is a prominent feature of cancer cells [9] and has been related with the 
glycosylation profile in malignant tissues [163]. In fact, previous work showed in 
bladder cancer cells that hypoxia enhanced the expression of the STn structure, 
which in turn increased malignant characteristics [164]. The overexpression of 
truncated O-glycans, which leads to increased CD44icd-dependent gene 
activation (due to increased cleavage), could be one of the responsible 
mechanisms involved in the maintenance of truncated O-glycans expression in 
cancer cells, in a positive feedback loop. This hypothesis could have implications 
in vivo. In fact, results showed a co-localization of CD44v9 with Tn and STn in 
GC tissue samples. Knowing that truncated O-glycans facilitate CD44 
extracellular cleavage, this event could be observed in vivo, enabling the use of 
cleaved CD44v9 with truncated O-glycans as a serum biomarker for tumor 
progression. This could also explain why this specific variant was found in sera 
of GC patients [165]. Therefore, the ELISA protocol for the detection of this 
specifically glycosylated CD44 isoform could be applied in clinical practice, with 
clear implications for GC patient’s care and overall survival. 
 Glycobiology adds an additional layer of complexity to biological 
processes, as it is a non-templated post-translational modification. The potential 
alterations due to glycosylation changes in cancer constitute a major point of 
attention in research and clinal practice. 
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 The use of specific CD44v for cancer treatment was already addressed in 
the Introduction chapter. One example of its failure is based on the expression of 
a cancer-related variant, CD44v6, in the human skin epithelium. CD44v9 was 
also shown to be expressed in the human skin epithelial cells [166], what could 
compromise its use in GC therapeutic or biomarker applications. However, when 
the glycoprofile of the cells is taken into account, CD44v9 with truncated O-
glycans could be cancer-unique, as the human skin epithelium was shown to be 
STn and Tn negative [130]. Therefore, it would have been crucial to consider in 
the referred CD44v6 therapeutic target, that the glycoprofiles of skin and cancer 
cells are completely different, which could be used to differentiate them. This 
failed clinical trial exemplifies how important glycosylation is to consider when 


















 In this thesis, results have been generated on the impact of truncated O-
glycans in cancer associated CD44 variants, suggesting that these glycan 
structures promote oncogenic features of CD44. The main conclusions of the 
work are: 
• CD44v9 has a cancer-specific detection in gastric and colorectal cancer 
tissue cohorts, showing co-expression with STn in the GC samples, and a 
statistically significant association with tumor size in CRC TMAs; 
• Truncated O-glycans influence molecular features of CD44 and its variant 
isoforms: antibody detection, molecular weight and cellular distribution 
of CD44v9 and CD44s; 
• The presence of CD44v9 protein or its recognition is clearly enhanced by 
immature O-glycans but not N-glycans; 
• The transcription of CD44v9 and CD44s does not seem to be influenced 
by truncated O-glycans; 
• O-glycans modulate protease sensitivity of CD44v9 and CD44s. 
  
 These findings have special relevance in cancer development, providing 
promising directions to identify a serum biomarker and a target for treatment, 
and demonstrating that glycosylation cannot be neglected in detecting and 







FUTURE PROSPECTS  
   
 This thesis provides the baseline knowledge for future studies regarding 
the influence of CD44v9 glycoprofile on its malignant functions, as this 
protein/truncated glycans association may improve its specificity as a biomarker 
and therapeutic target. The work presented will be submitted to a peer-review 
journal, resulting in a published article. Moreover, the risen hypothesis deserves 
clarification. Therefore, a one-year project was designed to unravel CD44 
glycoforms in GI cancer, with the following aims: 
1. Detect a CD44v9 specific glycoform in the serum of GI cancer patients; 
2. Characterize in vitro the CD44 protein dynamins in a context of O-
glycosylation truncation; 
3. Establish the contribution of CD44 pathways in the cancer-related 
aberrant immature O-glycans presence. 
 This project will fulfill, in a very specific way, several gaps that currently 
exist regarding the impact of glycosylation in important cancer biomarkers.
  
 
 Finally, the long-term prospect is the implementation in the clinical 
practice of a biomarker based on the presence of CD44v9 glycoforms both in 
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